



DRI HEALTHCARE TRUST

MANAGEMENT'S DISCUSSION AND ANALYSIS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025

DRI HEALTHCARE TRUST

MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025

BASIS OF PRESENTATION	1
ADDITIONAL INFORMATION	1
FORWARD-LOOKING INFORMATION	1
REFERENCES AND DEFINED TERMS	2
USE OF NON-GAAP MEASURES	2
OVERVIEW OF THE TRUST	2
EXPLANATORY NOTE REGARDING THE RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS	2
BUSINESS AND STRATEGY OVERVIEW	3
FINANCIAL REVIEW: RESULTS OF OPERATIONS	8
FINANCIAL REVIEW: NON-GAAP FINANCIAL MEASURES	16
FINANCIAL REVIEW: FINANCIAL POSITION	20
FINANCIAL REVIEW: CASH FLOWS	24
EQUITY	24
LIQUIDITY AND CAPITAL RESOURCES	27
OFF-BALANCE SHEET OBLIGATIONS AND COMMITMENTS	27
RELATED-PARTY TRANSACTIONS	27
CHANGES IN ACCOUNTING POLICIES	28
CRITICAL ACCOUNTING ESTIMATES	29
RISK FACTORS	29
SUBSEQUENT EVENTS	29

MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025

BASIS OF PRESENTATION

The following interim Management's Discussion and Analysis ("**MD&A**") is intended to help the reader understand the results of operations and financial condition of DRI Healthcare Trust (together with its consolidated subsidiaries, the "**Trust**"). This MD&A is provided as a supplement to, and should be read in conjunction with, the unaudited interim condensed consolidated financial statements of the Trust for the three and nine months ended September 30, 2025 (the "**consolidated financial statements**"), as well as the audited annual consolidated financial statements of the Trust for the year ended December 31, 2024 (the "**2024 consolidated financial statements**"), including the accompanying notes to such financial statements. The consolidated financial statements of the Trust have been prepared in accordance with IFRS[®] Accounting Standards as issued by the International Accounting Standards Board ("**IASB**").

We present our financial statements in United States dollars ("**U.S. dollars**"). In this MD&A, all dollar amounts are expressed in U.S. dollars unless otherwise indicated. Accordingly, all references to "**US\$**", "**\$**" or "**dollars**" are to U.S. dollars, and all references to "**C\$**" are to Canadian dollars. Certain totals, subtotals and percentages throughout this MD&A may not reconcile due to rounding. Dollar amounts in the tables and elsewhere in this MD&A are presented in thousands of U.S. dollars except per unit data or unless otherwise noted.

The board of trustees of DRI Healthcare Trust has approved this disclosure.

This MD&A is prepared as of November 5, 2025.

ADDITIONAL INFORMATION

Additional information relating to the Trust, including the Trust's annual and interim quarterly consolidated financial statements and management's discussion and analyses, annual information form and management information circular, are available on SEDAR+ at www.sedarplus.ca. Solely for convenience, the products underlying our royalty assets may appear without the [®] or [™] symbol, but such references are not intended to indicate, in any way, that the owners of such trademarks will not assert their rights to such trademarks.

FORWARD-LOOKING INFORMATION

This MD&A contains forward-looking information within the meaning of applicable securities laws in Canada. Forward-looking information may relate to our future financial outlook and anticipated events or results, and may include information regarding our financial position, business operations, business strategy, growth strategies, budgets, operations, financial results, taxes, distribution policy, plans and objectives.

In certain cases, forward-looking information includes statements that are predictive in nature, depend upon or refer to future events or conditions, and/or can be identified by the use of words such as "expect", "continue", "anticipate", "intend", "aim", "plan", "believe", "budget", "estimate", "forecast", "foresee", "close to", "target" or negative versions thereof and similar expressions, and/or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, although not all forward-looking information contains these terms and phrases. Any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. In particular statements pertaining to the regulatory and clinical development of veligrotag and VRDN-003, anticipated product commercialization, and the timing and amount of potential royalty payment and product sales. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events or circumstances.

Forward-looking information involves known and unknown risks and uncertainties, many of which are beyond our control, that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. For instance, without limitation, the anticipated royalty terms for products in our portfolio may be shorter than the period of patent protection for the applicable product, depending on many factors, including the entry of generic drugs into the marketplace and competition, all of which are outside our control. These risks and uncertainties also include, but are not limited to, the general economic and industry conditions, reliance on debt financing, our ability to leverage our competitive strength, and those described in greater detail under "Risk Factors" in the Trust's most recent annual information form, available under our profile on SEDAR+ at www.sedarplus.ca.

Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information, there may be other risk factors not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information or interpret or regard forward-looking statements as guarantees of future outcomes. The forward-looking information contained in this MD&A has been prepared taking into consideration information available only to the date of this MD&A, or as of the date it is otherwise stated, and is subject to change after such date. However, we disclaim any intention, obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws in Canada.

REFERENCES AND DEFINED TERMS

All references in this MD&A to the “Trust”, “we”, “us” and “our” are to DRI Healthcare Trust, together with its consolidated subsidiaries.

In this MD&A, the terms “royalties”, “royalty assets”, “royalty entitlements”, “royalty agreements” and “royalty streams” are used interchangeably to refer to either: (i) contractual arrangements that grant the buyer the right to receive royalties derived from the sale of pharmaceutical, biotechnology and other life science products pursuant to license agreements or other contractual arrangements (we refer to these as “**traditional**” royalty streams); or (ii) contractual arrangements that grant the buyer the right to receive a percentage of the top-line sales of pharmaceutical, biotechnology and other life science products directly from the marketer of the product (we refer to these as “**synthetic**” royalty streams). When we refer to having “**bought royalties**” on the sales of a particular product, or where we use similar expressions, we are generally referring to us having entered into the contractual arrangement that creates the traditional royalty or synthetic royalty stream in our favor. Unless the context otherwise requires, when we refer to terms such as “**our royalties**”, “**our portfolio**”, “**our royalty portfolio**”, “**our interests in products**” and similar terms, we are referring to our contractual interests in royalties and royalty streams that are held by our subsidiaries. When we refer to “**products**” and “**therapeutics**”, we are referring to the pharmaceutical, biotechnology or other life science products related to our royalties. When we refer to the “**pharmaceutical industry**”, we are referring generally to the pharmaceutical, biotechnology and other life science products industry.

USE OF NON-GAAP MEASURES

This MD&A contains a number of financial performance measures and ratios that have been calculated using methodologies which are not in accordance with IFRS Accounting Standards (“**non-GAAP measures**”). These non-GAAP measures do not have a standardized meaning as prescribed by IFRS Accounting Standards and therefore are unlikely to be comparable to similar measures presented by other companies. We believe that providing these non-GAAP measures, in addition to our results under IFRS Accounting Standards, gives investors additional information for understanding the critical components of our financial performance. Accordingly, these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our financial information reported under IFRS Accounting Standards. These non-GAAP measures are used to provide investors with a supplemental measure of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS Accounting Standards measures. We also believe that securities analysts, investors and other interested parties frequently use non-GAAP measures in the evaluation of issuers. We rely on these measures in the day-to-day management of our business, assessment of investment opportunities and assessment of our liquidity and borrowing needs.

Our uses, definition and calculation methodology, and the reconciliations of these non-GAAP measures to the most directly comparable measures calculated and presented in accordance with IFRS Accounting Standards, if available, for each of the measures, are presented under “Financial Review: Non-GAAP Financial Measures” on page 16 of this MD&A. The Trust has presented the following non-GAAP measures in this MD&A:

- Total Cash Receipts;
- Normalized Total Cash Receipts;
- Total Cash Royalty Receipts;
- Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“**Adjusted EBITDA**”);
- Adjusted EBITDA Margin; and
- Adjusted Cash Earnings per Unit.

OVERVIEW OF THE TRUST

DRI Healthcare Trust was established as an unincorporated open-ended limited purpose trust under the laws of the Province of Ontario pursuant to a declaration of trust on October 21, 2020, as amended and restated on May 15, 2025. DRI Healthcare Trust is a “mutual fund trust” within the meaning of the *Income Tax Act* (Canada), but not a “mutual fund” within the meaning of applicable Canadian securities legislation. Effective July 1, 2025, DRI Healthcare Trust became a specified investment flow-through (“**SIFT**”) trust for the purposes of the *Income Tax Act* (Canada). DRI Healthcare Trust’s head and registered office is located at First Canadian Place, Suite 6200, 100 King Street West, Toronto, Ontario, M5X 1B8.

All references in this MD&A to “**former external manager**” are to Persis Capital Inc. (formerly DRI Capital Inc.). The former external manager provided management and other services to us up to June 30, 2025, pursuant to the terms of a management agreement. On July 1, 2025, the Trust completed the internalization of its investment management function and terminated the management agreement between the Trust and the former external manager, as described on page 5 of this MD&A.

DRI Healthcare Trust’s Units (each a “**Unit**”, and collectively “**Units**”) are listed on the Toronto Stock Exchange (“**TSX**”) in Canadian dollars under the symbol “**DHT.UN**” and in U.S. dollars under the symbol “**DHT.U**”.

EXPLANATORY NOTE REGARDING THE RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS

In the second quarter of 2024, the Audit Committee of the board of trustees of the Trust, assisted by independent legal counsel and forensic accountants, commenced an internal investigation into irregularities related to certain alleged consulting and other expenses charged to the Trust, either directly or indirectly, by the former external manager, as directed by the former Chief Executive Officer. As a consequence of the investigation, it was determined that the Trust should not have been charged certain consulting and other expenses. These charges were made during periods from and including fiscal 2021 through June 30, 2024 and totaled \$6,510.

As a result, on August 6, 2024, the Trust restated its financial statements as at December 31, 2023 and the year then ended.

There has been no change to the amount of cash royalties received from any of the assets in any previous term nor has there been any change to the forecast of future royalty receipts as a result of these findings.

On July 9, 2024 and August 6, 2024, the former external manager reimbursed the Trust a total amount of \$6,510, of which \$6,196 was recorded in other equity and \$314 reduced a related-party receivable from the former external manager.

BUSINESS AND STRATEGY OVERVIEW

Business Overview

We excel at sourcing, evaluating and completing transactions to purchase royalties paid on the sales of leading therapeutics. We do this by leveraging a track record of disciplined capital deployment, the skills and competencies of our highly skilled team, and our proprietary sourcing and diligence systems. We accelerate therapeutic innovation by providing capital to leading inventors working at top universities and research institutions, academic institutions, biotechnology companies and large pharmaceutical companies. We provide our holders of Units ("**Unitholders**") with exposure to a broadly diversified portfolio of therapeutics that we expect will grow significantly in the medium and long term. We target royalties on products with the following characteristics:

- Medically necessary products that effectively treat chronic and critical illnesses;
- Products that benefit from strong intellectual property and/or regulatory protection; and
- Products that are marketed by leading biopharmaceutical companies.

As at September 30, 2025, our portfolio consisted of 28 royalty streams on 21 products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, lysosomal storage disorders ("**LSD**") and immunology. Many of the royalty streams in our portfolio provide us with entitlements on products that we believe represent focus areas and important revenue sources for their respective marketers. The approved products underlying our royalty entitlements are marketed by leading global pharmaceutical and biotechnology companies, including Apellis Pharmaceuticals Inc. ("**Apellis**"), Biogen Inc. ("**Biogen**"), GSK plc ("**GSK**"), Galderma S.A. ("**Galderma**"), Johnson & Johnson Services, Inc. ("**Johnson & Johnson**"), KalVista Pharmaceuticals, Inc. ("**KalVista**"), Menarini Group ("**Menarini**"), Novartis AG ("**Novartis**"), Rayner Surgical Inc. ("**Rayner Surgical**"), Regeneron Pharmaceuticals Inc. ("**Regeneron**"), Hoffman-La Roche AG ("**Roche**"), Sanofi S.A. ("**Sanofi**"), Swedish Orphan Biovitrum AB ("**Sobi**"), and Vertex Pharmaceuticals Inc ("**Vertex**").

Unique Growth Strategy

We are focused on providing our Unitholders with top-line exposure to a portfolio of attractive therapeutics by purchasing royalties on growing products that meet our investment criteria. We target an underserved niche that leverages the competitive advantages that the Trust has developed, including the specialized expertise of its team members and its access to data and information through its proprietary tools and know-how.

We believe the Trust has a number of advantages that are hard to replicate. One of these advantages is our proprietary database that is used to source transactions. This database tracks over 7,500 royalties on over 2,500 drugs worldwide. Another advantage is the deep relationships we have developed in our industry. Our target is to complete over \$1.25 billion in transactions from the time of our initial public offering in February 2021 to the end of 2025, which we believe will allow us to generate sustainable annual growth in cash receipts. We expect to fund our royalty transactions predominantly using our cash on hand and through the prudent use of leverage. Since our initial public offering through to September 30, 2025, we have deployed \$1.09 billion in 15 royalty transactions related to 13 products and made additional investments by way of loans and private investment in public equity. In connection with these transactions, there is the potential for further deployment of up to \$185 million pursuant to milestone obligations.

Our Assets

The Trust's assets currently comprise royalties on products that address a variety of therapeutic areas, such as oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, LSD and immunology. These products are marketed by leading global pharmaceutical and biotechnology companies, including Apellis, Biogen, GSK, Galderma, Johnson & Johnson, KalVista, Menarini, Novartis, Rayner Surgical, Regeneron, Roche, Sanofi, Sobi and Vertex. In addition, the Trust holds a financial royalty asset that it acquired from the Casgevy transaction and an equity investment in KalVista that the Trust acquired in connection with the Ekterly transaction. The Casgevy royalty is classified as a financial royalty asset for accounting purposes due to the nature of the contractual cash flows. Our other royalties are classified as intangible royalty assets for accounting purposes.

We receive royalty payments based on the sales of pharmaceutical products in particular geographies. In general, when sales of these products increase, the payments we receive through our royalties also increase. The sales of products in turn can be affected by a number of factors, including regulatory approvals in new markets, the competitive landscape for the product and the approval of a product for new uses. We may also receive milestone royalty income based on the achievement of regulatory and/or sales performance thresholds in accordance with the terms of the underlying royalty agreements. Milestone royalty income is recognized in royalty income once the milestone event is achieved.

The table below provides an overview of our royalty assets as at September 30, 2025, and outlines expected royalty expirations based on our estimates of patent expiry dates in key geographies and the contractual agreements of each royalty stream. These estimates may be impacted by regulatory, commercial or other product developments. Variance from the anticipated performance of royalty-bearing sales may also affect these estimates as a result of caps or other structuring elements. See "Risk Factors" in our most recent annual information form.

Royalty Asset	Therapeutic Area	Primary Marketer(s)	FDA Approval Date	Expected Royalty Expiry ^{(i), (ii)}
Casgevy ⁽ⁱⁱⁱ⁾	Hematology	Vertex Pharmaceuticals	December 2023	Q1 2034
Ekterly	Immunology	KalVista	July 2025	Q1 2042
Empaveli/Syfovre ^{(iv), (v)}	Hematology/Ophthalmology	Apellis, Sobi	May 2021	Q4 2033
Eylea I	Ophthalmology	Regeneron, Bayer, Santen	November 2011	Q1 2027
Eylea II	Ophthalmology	Regeneron, Bayer, Santen	November 2011	Q1 2027
Natpara	Endocrinology	Takeda	January 2015	Q3 2025
Omidria	Ophthalmology	Rayner Surgical	May 2014	Q4 2031
Oracea	Dermatology	Galderma	May 2006	Q1 2028
Orserdu I	Oncology	Menarini	January 2023	Q1 2035
Orserdu II	Oncology	Menarini	January 2023	Q1 2035
Rydapt	Oncology	Novartis	April 2017	Q3 2028
Spinraza	Neurology	Biogen	December 2016	Q3 2031
Vonjo I	Hematology	Sobi	February 2022	Q2 2034
Vonjo II	Hematology	Sobi	February 2022	Q2 2034
Xenpozyme ^(vi)	Lysosomal Storage Disorder	Sanofi	August 2022	Q4 2036
Xolair	Immunology	Roche, Novartis	June 2003	Q2 2033
Zejula	Oncology	GSK	April 2022	Q2 2033
Zytiga	Oncology	Johnson & Johnson	September 2011 ^(vii)	Q2 2028

- (i) Represents the quarter during which the final royalty payment is expected and is based on our estimates of patent expiry dates in key geographies, loss of exclusivity and the contractual agreements of each royalty stream. These estimates may be impacted by regulatory, commercial or other product developments. Variance from the anticipated performance of royalty-bearing sales may also affect these estimates as a result of caps or other structuring.
- (ii) The anticipated royalty terms for products in our portfolio may be shorter than the period of patent protection for the applicable product, depending on many factors, including the entry of generic drugs into the marketplace and competition, all of which are outside our control.
- (iii) Casgevy is classified as a financial royalty asset due to the nature of the contractual cash flows from the transaction, as described on page 9 of this MD&A.
- (iv) On February 17, 2023, the FDA approved Syfovre (pegcetacoplan) as a treatment for geographic atrophy. The Trust's royalty entitlement on Syfovre is consistent with that of Empaveli.
- (v) Empaveli/Syfovre includes two royalty streams on each product as a result of the additional Empaveli and Syfovre streams acquired in Q2 2023.
- (vi) Xenpozyme includes two royalty streams as a result of the additional Xenpozyme stream acquired in Q2 2024.
- (vii) Represents the European Commission approval date.

Key Developments Related to our Assets

Ekterly

On July 7, 2025, the U.S. Food and Drug Administration ("FDA") approved Ekterly as the first and only oral on-demand therapy for treatment of hereditary angioedema ("HAE") attacks. The Trust expects to receive cash receipts related to the Ekterly royalty entitlement starting in Q4 2025.

Vonjo I and Vonjo II

Due to competitive pressures continuing to have a greater impact than initially anticipated combined with recent unfavorable net pricing changes impacting sales of Vonjo, these conditions represent indicators of potential impairment of the Trust's Vonjo I and Vonjo II intangible royalty assets. As such, we are required to determine the recoverable amounts to assess if the Vonjo assets are impaired. We calculated the recoverable amounts for Vonjo I and Vonjo II as at September 30, 2025 using a discounted cash flow model based on revised forecasted cash flows adjusted for the greater impact of competition, changes in net pricing and current market uptake of Vonjo. The key assumptions and sources of estimation uncertainty are related to the discount rate and future cash flows, including future sales of Vonjo and key competitors. Based on our analysis, the net book value of Vonjo II exceeded its recoverable amount, and the Trust recorded impairment of \$13,691 for Vonjo II as at September 30, 2025. Based on the updated forecast, the net book value of Vonjo I was lower than the recoverable amount and no impairment was recognized on this asset. As a result of recognizing the impairment, the net book value of the Vonjo II intangible royalty asset as at September 30, 2025 is \$39,015, which represents the recoverable amount.

Despite the Vonjo I and Vonjo II intangible royalty assets both relating to the same product, due to differences in the timing of the transactions, terms of the agreements and calculation of royalty entitlement, only the Vonjo II intangible royalty asset required impairment as a result of the revised cash flow forecast.

Orserdu

On December 26, 2024, as part of the Orserdu II transaction, the Trust received notice that certain pre-specified events outlined in the purchase agreement had occurred, and the milestone payment conditions had been met. Consequently, the Trust recognized an increase in the cost base of the Orserdu II royalty asset and a related other current liability of \$10,000, which was funded on January 24, 2025.

As a result of pre-specified events being met, certain royalty deductions have been exempted, leading to the recognition of an additional \$18,226 in royalty revenue for the year ended December 31, 2024. This includes \$15,745 related to the reclaiming of previous royalties and milestones earned since acquisition. The additional royalty revenue reclaimed is composed of (i) \$5,523 in milestones and \$9,589 in royalties for Orserdu II; and (ii) \$633 in milestones for Orserdu I. The exemption from certain deductions will apply at a similar rate to future royalties and milestones received.

Oracea

A subsidiary of Galderma, the marketer of Oracea, and TCD Royalty Sub LP, a subsidiary of the Trust (together, the "**Plaintiffs**"), had been engaged in patent infringement litigation with Lupin Inc. and Lupin Limited (together, "**Lupin**") in the U.S. District Court for the District of Delaware (the "**District Court**") since December 2021. Lupin had filed an abbreviated new drug application ("**ANDA**") with the FDA to manufacture a generic version of Oracea prior to the expiration of key patents to which Galderma is the exclusive license holder.

On April 1, 2024, the District Court issued a decision of non-infringement in favor of Lupin. Consequently, the Plaintiffs filed an appeal of the District Court's decision with the United States Court of Appeals for the Federal Circuit ("**CAFC**"). On April 9, 2024, Lupin launched its generic version of Oracea "at-risk" in the United States, prior to the appeal decision. On April 16, 2024, Galderma filed a motion for preliminary injunction to require Lupin to cease marketing its generic product while the appeal is pending and subsequently filed a motion to expedite the appeal. On May 9, 2024, the CAFC denied Galderma's motion for injunction pending appeal and granted the motion to expedite. In addition, since the time of Lupin's "at-risk" launch, and under the terms of their settlement agreements with the Plaintiffs, certain companies have received final ANDA approval for their generic versions of Oracea, and at least one of these companies has launched its product "at-risk". On September 5, 2024, the Federal Circuit heard oral arguments in the Lupin appeal. On December 6, 2024 the Federal Circuit affirmed for non-infringement of Lupin's generic product, allowing Lupin and other generics to stay on the market and additional generics to enter the market.

These events represented indicators of potential impairment of the Trust's Oracea royalty asset. As such, we were required to determine the recoverable amount of Oracea to assess if the asset is impaired. The recoverable amount as of December 31, 2024 was calculated using a discounted cash flow model based on revised cash flows adjusted for the impact of the launch of generic competition by Lupin and other generics. Based on our analysis, the net book value of Oracea exceeded the recoverable amount and the Trust recorded impairment of \$15,787 during the year ended December 31, 2024. As a result of recognizing the impairment, the net book value of the Oracea royalty asset as at December 31, 2024 was \$4,498, which represented the recoverable amount.

Other Key Events

Internalization

On July 1, 2025, the Trust completed the previously announced transaction to internalize its investment management function. In connection with the internalization the Trust and the former external manager had entered into a certain termination agreement pursuant to which (i) the management agreement with the former external manager was terminated, effective June 30, 2025; and (ii) the former external manager agreed to indemnify the Trust and its affiliates in respect of, among other things, damages, if any, related to the event described on page 2 of this MD&A under "Explanatory Note Regarding the Restatement of Previously Issued Consolidated Financial Statements". To extinguish the former external manager's management agreement, along with all management and performance fee obligations, the Trust paid a termination fee of \$48,000. The termination of the former external manager results in the elimination of management and performance fees on a go forward basis.

In addition, in connection with the internalization, the Trust acquired certain relevant assets of the former external manager for a purchase price of \$1,000. As a result of the transaction contemplated by a certain asset purchase agreement entered into between the Trust and the former external manager, the employees of the former external manager transitioned to a subsidiary of the Trust.

Normal Course Issuer Bid ("**NCIB**")

On May 9, 2025, we were granted approval by the TSX to acquire, from time to time, if considered advisable, up to 3,148,536 Units of the Trust for cancellation between May 20, 2025 and May 19, 2026 ("**May 2025 NCIB**"). In connection with the May 2025 NCIB, the Trust established an automated unit purchase plan ("**AUPP**") whereby Units of the Trust may be repurchased at the discretion of a dealer to the AUPP using commercially reasonable efforts and subject to trading parameters defined in the AUPP.

During the nine months ended September 30, 2025, the Trust acquired and canceled 1,351,897 Units at an average price of \$9.76, totaling \$13,193. As at September 30, 2025, in aggregate, we have acquired and canceled 4,515,406 Units at an average price per Unit of \$7.00, totaling \$31,620, under all current and previous normal course issuer bid plans ("**NCIB Plans**"). Our NCIB Plans are discussed further on page 25 of this MD&A.

From September 30, 2025 to November 5, 2025, we acquired an additional 53,076 Units under the May 2025 NCIB plan at an average price of \$10.28, totaling \$545 under the AUPP.

Credit Facility

On May 12, 2025, we received lender consent for the internalization of the manager function. We also further revised our amended credit agreement (as defined herein) to reallocate \$25,000 of the acquisition credit facility to the working capital credit facility, increasing it to \$50,000. The credit available for investment remains unchanged as the working capital credit facility can be used for investment purposes. Furthermore, the interest rate on the amended credit agreement was revised to the Secured Overnight Financing Rate ("**SOFR**") plus (i) a margin which may vary from 1.75% to 2.50% based on the Trust's leverage ratio; and (ii) a margin of 0.10%. All other material terms of the amended credit agreement remain unchanged. Our credit facility is discussed in further detail on page 21 of this MD&A.

On October 3, 2025, we amended our amended credit agreement to, among other things, convert and merge the term credit facility into the acquisition credit facility. The total credit available under the acquisition credit facility increased by \$70,000 and the outstanding amount under the acquisition credit facility increased by an amount corresponding to the outstanding amount under the term credit facility as at October 3, 2025, which was \$63,250. This increased the total credit available under the acquisition credit facility to \$570,000. The Trust also extended the maturity date of the amended credit agreement by two years to October 3, 2029, which may be extended by one-year increments subject to lender approval. Certain other terms were also adjusted to provide the Trust with greater flexibility. All other material terms of the amended credit agreement remain unchanged.

Interest Rate Swap

On June 10, 2025, to reflect changes resulting from amendments to the credit agreement, we extended the maturity on our original interest rate swap to November 1, 2027, and entered into a second interest rate swap agreement with equivalent terms for an additional notional amount of \$50,000. Under the agreements, we pay a fixed rate and in exchange receive a SOFR interest rate, offsetting the floating component on a portion of the credit facility. The interest rate swap is discussed in further detail on page 14 of this MD&A.

Preferred Securities

On June 18, 2025, we redeemed and canceled \$10,000 in face value of the Series C Preferred Securities ("**2024 Preferred Securities**") for \$9,500. We paid outstanding accrued interest on the \$10,000 face value up to and including June 18, 2025, the date of the transaction. The terms of the remaining 2024 Preferred Securities remain unchanged. The 2024 Preferred Securities are discussed in further detail on page 22 of this MD&A.

Distributions

During the three months ended September 30, 2025, the board of trustees of the Trust declared a quarterly cash distribution of \$0.10 per Unit totaling \$5,515 to Unitholders of record as at September 30, 2025, which was paid on October 20, 2025. On May 12, 2025 our board of Trustees declared a quarterly distribution of \$0.10 per Unit totaling \$5,550, to Unitholders of record as at June 30, 2025, which was paid on July 18, 2025. On March 3, 2025 our board of Trustees declared a quarterly distribution of \$0.10 per Unit totaling \$5,631 to Unitholders of record as at March 31, 2025, which was paid on April 17, 2025. Additionally, on January 20, 2025, we paid \$4,786 of cash distributions declared in 2024.

We pay quarterly distributions in accordance with our distribution policy. Distributions are discussed in further detail in note 8 to the consolidated financial statements.

Transactions Completed in 2025

Orserdu II Milestone Payment

On January 24, 2025, we paid \$10,000 to fund the Orserdu II milestone obligation as a result of certain pre-specified events outlined in the purchase agreement having been met.

Ekterly Optional Payment

On July 7, 2025, KalVista elected to receive the one-time optional payment of \$22,000 as part of the Ekterly transaction completed in 2024, as described on page 7 of this MD&A. As a result of the payment, the Trust's royalty entitlement on net sales up to and including \$500,000 increased from 5.0% to 6.0% and the potential one-time sales-based milestone payment to KalVista increased from \$50,000 to \$57,000. We funded the payment on July 9, 2025.

Veligrotug and VRDN-003 Transaction

On October 17, 2025, the Trust acquired a royalty interest in the U.S. net sales of veligrotug and VRDN-003 from Viridian Therapeutics, Inc. ("**Viridian**") for an aggregate purchase price of up to \$300,000, including a \$55,000 upfront payment and up to \$115,000 in near-term clinical and regulatory milestone payments. The transaction entitles the Trust to 7.50% on annual U.S. net sales up to and including \$600,000, 0.80% on annual U.S. net sales above \$600,000 and up to and including \$900,000, and 0.25% on annual U.S. net sales above \$900,000 and up to and including \$2,000,000. Royalty receipts will be collected quarterly on a one-quarter lag, with the first royalty receipt being paid in the quarter immediately following the first commercial sale of veligrotug in the U.S.

Veligrotug has shown clinically meaningful improvements across both active and chronic thyroid eye disease ("**TED**"). Veligrotug has met all primary and secondary endpoints across proptosis, Clinical Activity Score, and diplopia in each of its two pivotal phase 3 clinical trials, THRIVE-1 and THRIVE-2 for patients with active and chronic TED, respectively. The FDA has granted Breakthrough Therapy Designation to veligrotug, which may shorten certain aspects of the regulatory review process, including eligibility for priority review. If approved, veligrotug will be only the second approved biologic treatment for TED with the potential to improve patients' quality of life with fewer doses and less time required for a full treatment course.

Viridian is also advancing VRDN-003, a potential best-in-class subcutaneous therapy for the treatment of TED via a program including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, in patients with active and chronic TED, respectively. Viridian anticipates reporting topline results from these trials in the first half of 2026. Subject to positive outcomes and subsequent regulatory review, Viridian plans to submit a Biologics License Application by the end of 2026. If approved, VRDN-003 is expected to provide additional convenience benefits with a low-volume autoinjector designed for self-administration planned for commercial launch.

Transactions Completed in 2024

Omidria Royalty Amendment

On February 1, 2024, we expanded our interest in royalties on the United States net sales of Omidria by amending our existing Omidria royalty agreement entered into in 2022. For a purchase price of \$115,000, the amendment now entitles us to receive a 30% royalty on United States net sales of Omidria until December 31, 2031, and all previously agreed-upon annual royalty caps have been eliminated. As part of the amendment, we are no longer entitled to ex-U.S. royalties. In accordance with the terms of the amended royalty agreement, the royalty seller may be entitled to receive up to \$55,000 in potential sales-based milestone payments.

We recognized acquired royalties receivable of \$3,560 related to our royalty entitlement accrued from November 1, 2023 to February 1, 2024, the date of the amendment. Transaction costs of \$777 were capitalized as part of the royalty asset amendment.

Omidria was approved by the FDA in May 2014 and the European Medicines Agency ("**EMA**") in July 2015 for intracameral use during cataract surgery or intraocular lens replacement to maintain pupil dilation and reduce postoperative pain. Omidria is marketed worldwide by Rayner Surgical.

Additional Xenpozyme Royalty Stream

On June 28, 2024, we bought an additional royalty stream on Xenpozyme for \$13,250. This royalty is in addition to our existing Xenpozyme royalty purchased in 2022. The transaction entitles us to an additional royalty of approximately 1.0% on worldwide net sales of Xenpozyme. We are entitled to receive semi-annual royalty payments in respect of the net sales of Xenpozyme commencing on July 1, 2024 on a two-quarter lag from the respective half-year period. Transaction costs of \$315 were capitalized as part of the royalty transaction.

In accordance with the royalty agreement, additional milestone payments totaling up to \$32,500 may be paid upon achievement of certain performance-based thresholds.

Xenpozyme is the only product developed and approved for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency ("ASMD"), also known as Niemann-Pick disease types A, A/B and B, in pediatric and adult patients. ASMD is an extremely rare, progressive genetic disease with significant morbidity and mortality, especially among infants and children. Xenpozyme was approved in Japan in March 2022, by the European Commission in June 2022 and by the FDA in August 2022. Xenpozyme is marketed worldwide by Sanofi.

Casgevy Transaction

On October 3, 2024, we acquired a share of payment rights on a Cas9 gene-editing technology for Casgevy for a purchase price of \$57,000. The transaction entitles us to a share of the annual license fees, which range from \$5,000 to \$40,000, and include certain sales-based annual license fee increases. We are also entitled to receive a mid-double-digit percentage of a \$50,000 contingent payment eligible under the license agreement. The first payment was received in January 2025, and the term of the payment streams is expected to run until 2034. Transaction costs of \$1,940 were incurred and expensed as deal investigation and research costs in relation to the transaction during 2024.

Casgevy is the first treatment approved by the FDA to utilize CRISPR (clustered regularly interspaced short palindromic repeats) technology, a technology used to selectively modify the DNA of living organisms. Casgevy was approved by the FDA in December 2023 for the treatment of sickle cell disease ("SCD") and in January 2024 for the treatment of transfusion-dependent beta thalassemia ("TDT"), and by the EMA for the treatment of both SCD and TDT in February 2024. Casgevy is the only approved gene-edited cell therapy for SCD and TDT. Casgevy is marketed worldwide by Vertex Pharmaceuticals Inc.

Ekterly Transaction

On November 4, 2024, we acquired a royalty interest in the worldwide net sales of all formulations of the not-yet-approved Ekterly from KalVista for an aggregate purchase price of up to \$179,000, composed of a \$100,000 upfront payment, up to \$57,000 in a sales-based milestone payment and a one-time \$22,000 optional payment. The transaction entitles us to a tiered royalty of 5.0% on net sales up to and including \$500,000, 1.1% on net sales above \$500,000 and up to and including \$750,000, and 0.25% on net sales above \$750,000. Royalty payments are expected to be received quarterly commencing in the first quarter after FDA approval. Transaction costs of \$1,834 were capitalized as part of the royalty transaction.

Ekterly is the first and only oral on-demand therapy for treating attacks associated with HAE. HAE is a rare genetic disorder characterized by recurring episodes of severe swelling in various parts of the body, including the face, extremities, gastrointestinal tract and airways.

On July 7, 2025, Ekterly received FDA approval and KalVista elected to receive the one-time \$22,000 optional payment, which was funded on July 9, 2025. As a result of the payment, the Trust's royalty entitlement on net sales up to and including \$500,000 increased from 5.0% to 6.0% and the potential one-time sales-based milestone payment to KalVista increased from \$50,000 to \$57,000. Ekterly is marketed by KalVista.

In addition to the royalty entitlement, we also purchased in a private transaction 500,000 shares of KalVista common stock at a price of \$10 per share for a total cost of \$5,000.

Summary of Transactions Completed in 2024

The following is a summary of the transactions completed during the year ended December 31, 2024:

	Omidria Royalty Amendment	Additional Xenpozyme Transaction	Casgevy Transaction	Ekterly Transaction	Total for the year ended December 31, 2024
Assets					
Financial royalty asset	\$ —	\$ —	\$ 57,000	\$ —	\$ 57,000
Royalties receivable	3,560	—	—	—	3,560
Intangible royalty asset	111,440	13,250	—	100,000	224,690
Investment in marketable securities	—	—	—	5,000	5,000
Net acquired assets	\$ 115,000	\$ 13,250	\$ 57,000	\$ 105,000	\$ 290,250

FINANCIAL REVIEW: RESULTS OF OPERATIONS

During the three and nine months ended September 30, 2025, the Trust generated total income of \$48,745 and \$136,903, respectively (2024 – \$41,555 and \$125,226, respectively), and incurred total expenses of \$58,845 and \$147,408, respectively (2024 – \$43,247 and \$136,192, respectively). The Trust incurred a loss on preferred securities of \$971 during the nine months ended September 30, 2025 (2024 – gain of \$2,176) and paid a termination fee of \$48,000 during the three and nine months ended September 30, 2025 (2024 – nil). The Trust did not incur an other loss during the three and nine months ended September 30, 2025 (2024 – nil and \$1,575, respectively).

During the three and nine months ended September 30, 2025, the Trust also recorded a net unrealized fair value gain (loss) in other comprehensive earnings (loss) of \$184 and \$(972), respectively, related to its derivative instruments (2024 – \$(1,632) and \$(207), respectively), resulting in total comprehensive loss of \$57,676 and \$60,208, respectively (2024 – \$3,324 and \$10,572, respectively).

The following table presents the components of net earnings (loss) and comprehensive earnings (loss) and is followed by a discussion of the nature of significant sources of income and categories of expenses.

	Three months ended		Nine months ended	
	September 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024
Income				
Royalty income	\$ 46,884	\$ 40,959	\$ 131,311	\$ 123,331
Change in fair value of financial royalty assets	1,173	—	2,830	—
Unrealized gain (loss) on marketable securities	435	—	1,855	—
Other interest income	253	596	907	1,895
Total income	48,745	41,555	136,903	125,226
Expenses				
Amortization of intangible royalty assets	26,326	26,098	75,822	76,823
Impairment of intangible royalty assets	13,691	901	13,691	6,101
Management fees	—	1,470	6,733	8,459
Performance fees	—	—	533	231
Interest expense	10,252	8,377	28,887	25,416
Deal investigation and research expenses	1,119	1,056	3,531	3,923
Compensation expense ⁽ⁱ⁾	3,542	100	4,125	100
Unit-based compensation	1,150	347	2,580	7,589
General and administrative expenses ⁽ⁱ⁾	819	80	1,016	221
Other operating expenses ⁽ⁱ⁾	1,946	4,818	10,490	7,329
Total expenses	58,845	43,247	147,408	136,192
Gain (loss) on preferred securities	—	—	(971)	2,176
Other loss	—	—	—	(1,575)
Termination fee	(48,000)	—	(48,000)	—
Net earnings (loss) before tax	(58,100)	(1,692)	(59,476)	(10,365)
Income tax recovery	240	—	240	—
Net earnings (loss)	(57,860)	(1,692)	(59,236)	(10,365)
Other comprehensive earnings (loss)				
Net unrealized gain (loss) on derivative instruments	184	(1,632)	(972)	(207)
Comprehensive earnings (loss)	\$ (57,676)	\$ (3,324)	\$ (60,208)	\$ (10,572)

(i) Prior period figures have been adjusted to conform with the current period's classification.

Royalty income

Royalty income is comprised of income from our intangible royalty assets, which represents the contractual right to receive, directly or indirectly, a royalty payment, milestone royalty payment, license fee or any other form of compensation or benefit arising from or contingent upon the use of any patent, trade secret or any other form of intellectual property or other right relating to pharmaceutical drugs, devices and/or delivery technologies. The Trust typically does not own the licensed intellectual property; rather, it earns income based on rights to a royalty stream generally tied to the related underlying patent, calculated as a percentage of sales revenue generated by a third party at the time the sales occur. Royalty income is recorded on an accrual basis when earned in accordance with our contractual rights. Management is required to make estimates of royalty income earned for which a report or actual cash royalty receipts have not been received from our counterparty. Actual royalty receipts are reported and paid by our counterparties typically one or more quarters after they are earned. Actual milestone royalty receipts are received after the milestone condition has been met and they are paid in accordance with the terms of the agreement with the counterparty.

The following table presents the Trust's royalty income by intangible royalty asset for the three and nine months ended September 30, 2025 and 2024:

	Three months ended September 30, 2025	Three months ended September 30, 2024	% Change	Nine months ended September 30, 2025	Nine months ended September 30, 2024	% Change
Intangible Royalty Assets						
Eκτηrly	\$ 821	\$ —	n/a	\$ 821	\$ —	n/a
Empaveli/Syfovre ⁽ⁱ⁾	123	(103)	(219)%	4,900	5,233	(6)%
Eylea I	1,244	1,455	(15)%	3,612	4,068	(11)%
Eylea II	268	315	(15)%	778	879	(11)%
Natpara	149	370	(60)%	756	1,474	(49)%
Omidria	9,152	8,841	4 %	24,403	28,440	(14)%
Oracea	811	1,450	(44)%	2,913	5,880	(50)%
Orserdu I	9,535	7,419	29 %	24,055	18,163	32 %
Orserdu II	9,535	5,838	63 %	24,715	13,181	88 %
Rydapt	805	263	206 %	3,238	2,892	12 %
Spinraza	3,772	4,018	(6)%	11,265	10,721	5 %
Vonjo I	3,045	2,601	17 %	8,489	9,916	(14)%
Vonjo II	662	688	(4)%	1,862	2,226	(16)%
Xenpozyme ⁽ⁱⁱ⁾	1,165	1,234	(6)%	3,513	2,219	58 %
Xolair	3,782	3,213	18 %	10,491	9,120	15 %
Zejula	1,228	1,052	17 %	3,463	3,058	13 %
Zytiga	391	1,851	(79)%	773	4,545	(83)%
Other Products ⁽ⁱⁱⁱ⁾	396	454	(13)%	1,264	1,316	(4)%
Total Royalty Income	\$ 46,884	\$ 40,959	14 %	\$ 131,311	\$ 123,331	6 %

(i) Empaveli/Syfovre includes two royalty streams on each product held directly.

(ii) Xenpozyme includes two royalty streams as a result of the additional Xenpozyme stream acquired in Q2 2024, as described on page 7 of this MD&A.

(iii) Other Products includes intangible royalty assets which are not individually material, as well as intangible royalty assets which are fully amortized or, where applicable, the entitlements to which have substantially expired. Stelara, Simponi and Ilaris current period and comparative results have been moved to Other Products starting in Q1 2025.

The Trust records royalty income from intangible royalty assets from the date on which the Trust obtains control of those assets, which is typically the date on which the agreement creating the intangible royalty assets is entered into.

Royalty income for the three months ended September 30, 2025 was \$46,884 (2024 – \$40,959). The increase in royalty income is primarily due to (i) higher net sales of Orserdu, as well as additional royalties on Orserdu II due to certain royalty deductions becoming exempt that were not in effect for the prior period, as described on page 4 of this MD&A; (ii) royalty income from Eκτηrly, which received FDA approval in Q3 2025, as described on page 4 of this MD&A; and (iii) the increase in royalty income for Zejula due to lower net deductions on our royalty entitlement. The increase was partially offset by (i) a decrease in sales for Natpara; (ii) the decrease in sales for Oracea due to the launch of competitive generic products; and (iii) an expected decrease in royalty entitlements for Zytiga in certain non-U.S. geographies due to the entry of generic equivalents in these geographies.

Royalty income for the nine months ended September 30, 2025 was \$131,311 (2024 – \$123,331). The increase in royalty income is primarily due to (i) higher net sales on Orserdu I and Orserdu II, as well as additional royalties on Orserdu II due to certain royalty deductions becoming exempt that were not in effect for the prior period, as described on page 4 of this MD&A; (ii) royalties from an additional royalty stream on Xenpozyme, which was acquired during the second quarter of 2024; (iii) royalty income from Eκτηrly, which received FDA approval in Q3 2025, as described on page 4 of this MD&A; and (iv) an increase in sales for Xolair. The increase was partially offset by (i) the expected decrease in royalty entitlements for Zytiga in certain non-U.S. geographies due to the entry of generic equivalents in these geographies; (ii) a decrease in sales for Omidria; (iii) a decrease in sales for Vonjo I and Vonjo II due to competitive pressures and unfavorable net pricing; (iv) the decrease in sales for Oracea due to the launch of generic products; and (v) a decrease in sales for Natpara.

Change in fair value of financial royalty assets

On October 3, 2024, the Trust acquired a financial royalty asset through the Casgevy transaction, as described on page 7 of this MD&A. As a result of the nature of the contractual cash flows from the transaction, which primarily consist of fixed and determinable amounts not dependent on the underlying pharmaceutical product, the Trust's entitlement to the royalty license payment streams is classified as a financial royalty asset and changes in fair value are recognized in net earnings. During the three and nine months ended September 30, 2025 the Trust recognized a gain of \$1,173 and \$2,830, respectively (2024 – nil and nil, respectively), as a result of changes in the fair value of financial royalty assets.

Unrealized gain (loss) on marketable securities

As part of the Eκτηrly transaction, as described on page 7 of this MD&A, the Trust purchased 500,000 shares of KalVista common stock in a private transaction for \$10 per share for a total purchase price of \$5,000. Changes in the fair value of marketable securities are recognized in net earnings (loss). During the three and nine months ended September 30, 2025 the Trust recognized a gain of \$435 and \$1,855, respectively (2024 – nil and nil, respectively).

Amortization of intangible royalty assets

Intangible royalty assets are amortized over the estimated economic useful life of the assets, as described in note 3(c) to the Trust's 2024 consolidated financial statements. The Trust amortizes its intangible royalty assets beginning on the date on which the Trust begins receiving economic benefit from the royalty asset. During the three and nine months ended September 30, 2025, the Trust recorded amortization of intangible royalty assets of \$26,326 and \$75,822, respectively (2024 – \$26,098 and \$76,823, respectively).

The increase in amortization expense during the three months ended September 30, 2025 is primarily due to the amortization incurred on Ekerly, which did not incur amortization during the same period in 2024 as it received FDA approval in Q3 2025, as described on page 4 of this MD&A.

The decrease in amortization expense during the nine months ended September 30, 2025 compared to the same period in 2024 is primarily due to lower amortization on Oracea as its net book value was reduced due to impairment deductions taken against the asset during 2024, as described in the "Impairment of intangible royalty assets" section below.

Impairment of intangible royalty assets

During the three and nine months ended September 30, 2025, an impairment loss of \$13,691 was recognized related to the Vonjo II intangible royalty asset, as described on 4 of this MD&A. Due to the impairment indicators identified, the Vonjo II asset's net recoverable amount was calculated using an adjusted cash flow forecast and a discount rate of 8%. The difference between the calculated recoverable amount and the net book value was recorded as an impairment.

During the three and nine months ended September 30, 2024, an impairment loss of \$901 and \$6,101, respectively, was recognized related to the Oracea royalty asset. Due to the impairment triggers described on page 4 of this MD&A, the Oracea royalty asset's net recoverable amount was calculated using a cash flow forecast unadjusted for the impact of generic entrance and a discount rate of 12%. The difference between the calculated recoverable amount and the net book value was recorded as an impairment.

The impairment loss is recognized in the consolidated statements of net earnings and comprehensive earnings.

Management fees

The Trust recorded management fees of nil and \$6,733 during the three and nine months ended September 30, 2025, respectively (2024 – \$1,470 and \$8,459, respectively).

The decrease in management fees for the three and nine months ended September 30, 2025 compared to the same periods in 2024 is due to the internalization of the management function effective July 1, 2025 as described on page 5 of this MD&A, which resulted in the termination of the management agreement between the Trust and the former external manager. As a result of the termination, management fees will no longer be incurred going forward.

Performance fees

The Trust recorded performance fees of nil and \$533 during the three and nine months ended September 30, 2025, respectively (2024 – nil and \$231, respectively), as the conditions for performance fee payments were met primarily due to the cash receipt on Casgevy.

The performance fee recognized during the nine months ended September 30, 2024 was related to a true-up to the finalized calculation for performance fees that were accrued in the fourth quarter of 2023 and finalized in the first quarter of 2024. Due to the internalization of the management function effective July 1, 2025 as described on page 5 of this MD&A, which resulted in the termination of the management agreement between the Trust and the former external manager, performance fees will no longer be incurred going forward.

Interest expense

The Trust's interest expense relates to interest paid on the Trust's credit facility and interest on the 2024 Preferred Securities. Interest expense for the three and nine months ended September 30, 2025 and 2024 is presented below. The increase in interest expense is primarily due to (i) an increased face value and interest rate on the 2024 Preferred Securities due to the preferred security refinancing transaction in the second quarter of 2024, as described on page 23 of this MD&A; and (ii) a higher balance drawn on the Trust's credit facility. The Trust's long-term debt is discussed further on page 21 of this MD&A.

The increase to interest expense on the credit facility is partially offset by the Trust's interest rate swap. The Trust entered into a second interest rate swap agreement on June 10, 2025. In aggregate, the Trust swaps floating for fixed interest rates on a notional amount of \$150,000 of the Trust's credit facility, as further described on page 22 of this MD&A. The Trust uses the interest rate swap as a derivative financial instrument designated as a cash flow hedge to manage interest rate risk related to its credit facility.

During the three and nine months ended September 30, 2025, the Trust received net settlements of \$18 and \$57, respectively, on the interest rate swap (2024 – \$178 and \$531, respectively).

		Three months ended September 30, 2025		Three months ended September 30, 2024		Nine months ended September 30, 2025		Nine months ended September 30, 2024
Interest on credit facility net borrowings	\$	6,016	\$	4,451	\$	16,301	\$	14,009
Standby fees		276		294		886		848
Amortization of deferred transaction costs		513		203		1,044		946
Interest incurred (earned) on interest rate swap		(18)		(178)		(57)		(531)
Total interest expense on credit facility	\$	6,787	\$	4,770	\$	18,174	\$	15,272
Interest on preferred securities	\$	2,367	\$	2,556	\$	7,371	\$	6,975
Accretion of par value		959		914		2,891		2,741
Amortization of deferred transaction costs		139		137		451		428
Total interest expense on preferred securities	\$	3,465	\$	3,607	\$	10,713	\$	10,144
Total interest expense	\$	10,252	\$	8,377	\$	28,887	\$	25,416

Deal investigation and research expenses

Deal investigation and research expenses include the ongoing costs associated with the Trust's research and due diligence activities and other expenses necessary for the assessment of potential asset acquisition opportunities, including consulting, legal, research data and data subscription expenses.

For the three and nine months ended September 30, 2025, the Trust recorded deal investigation and research expenses of \$1,119 and \$3,531, respectively (2024 – \$1,056 and \$3,923, respectively). The increase for the three months ended September 30, 2025 compared to the same period in 2024 is primarily due to higher legal costs incurred in 2025 related to maintaining the existing portfolio, partially offset by lower consulting fees incurred. The decrease in deal investigation and research expenses for the nine months ended September 30, 2025 compared to the same period in 2024 is primarily due to lower consulting fees incurred and no valuation services engaged in 2025, partially offset by higher legal costs incurred in 2025 related to maintaining the existing portfolio.

Directly attributable costs associated with successful acquisitions of intangible royalty assets are capitalized as part of the cost of the royalty asset, in accordance with IFRS Accounting Standards as issued by the IASB.

Compensation expense

Previously, compensation expense was included in other operating expenses in the statements of net earnings and comprehensive earnings and only included compensation related to the Trust's Chief Executive Officer and Chief Financial Officer. With the completion of the internalization transaction on July 1, 2025, a wholly owned subsidiary of the Trust hired the employees of the former external manager, as described on page 5 of this MD&A. For the three months ended September 30, 2025 onwards, compensation expense reflects the compensation for these employees as well as the Trust's Executive Officers and was reclassified into a separate financial statement line expense.

During the three and nine months ended September 30, 2025, the Trust recognized compensation expense of \$3,542 and \$4,125, respectively (2024 – \$100 and \$100, respectively). On a comparative basis for the three and nine months ended September 30, 2025, compensation expense increased by \$3,442 and \$4,025, respectively, which was primarily driven by higher employee levels and one-time organizational restructuring expenses due to internalization. The one-time organizational restructuring costs were \$709 and consisted of severance expense related to the former Chief Financial Officer of the Trust.

Unit-based compensation

The Trust provides unit-based compensation under its Omnibus Equity Incentive Plan, as described in note 3(p) to the Trust's 2024 consolidated financial statements.

For the three and nine months ended September 30, 2025, the unit-based compensation expense was \$1,150 and \$2,580, respectively (2024 – \$347 and \$7,589, respectively), and was composed of Restricted Unit ("RU") grants, net of RUs vesting and any RU forfeitures during the period. As at September 30, 2025, the unit-based compensation liability was \$1,464 (December 31, 2024 – \$2,333), composed of a current portion of \$1,386 (December 31, 2024 – \$2,093) and a long-term portion of \$78 (December 31, 2024 – \$240) related to the outstanding awards.

The following table provides the details of RU grants up to September 30, 2025:

	Restricted Units
Balance – January 1, 2024	348,358 Units
Restricted Units granted:	
Granted on January 10, 2024 ⁽ⁱ⁾	370,128 Units
Granted on January 10, 2024 ⁽ⁱⁱ⁾	21,232 Units
Granted on May 1, 2024 ⁽ⁱⁱⁱ⁾	19,500 Units
Granted on May 31, 2024 ^(iv)	117,245 Units
Granted on May 31, 2024 ^(v)	233,333 Units
Granted on August 13, 2024 ^(vi)	110,752 Units
Distribution equivalent Units granted ^(vii)	14,601 Units
Vesting of Restricted Units	(634,127) Units
Balance – September 30, 2024	570,602 Units
Restricted Units granted:	
Distribution equivalent Units granted ^(vii)	4,453 Units
Vesting of Restricted Units	(79,170) Units
Forfeiture of Restricted Units	(58,514) Units
Balance – December 31, 2024	437,371 Units
Restricted Units granted:	
Granted on July 1, 2025 ^(viii)	99,254 Units
Granted on July 1, 2025 ^(ix)	99,254 Units
Granted on September 4, 2025 ^(x)	7,580 Units
Granted on September 4, 2025 ^(xi)	13,125 Units
Distribution equivalent Units granted ^(vii)	10,123 Units
Vesting of Restricted Units	(348,078) Units
Forfeiture of Restricted Units	(4,243) Units
Balance – September 30, 2025	314,386 Units

(i) Vested equally on June 15, 2024 and June 15, 2025.

(ii) Vested on April 1, 2024.

(iii) Vesting equally on September 10, 2024, September 10, 2025 and September 10, 2026.

(iv) Vesting equally on May 31, 2024, May 31, 2025 and May 31, 2026.

(v) Vested immediately on May 31, 2024.

(vi) Vesting equally on a quarterly basis beginning November 13, 2024 until August 13, 2026.

(vii) All RUs are credited with distribution equivalents in the form of additional RUs on each distribution payment date in respect of which normal distributions are paid on the Trust's Units. Such distribution equivalents are subject to the same vesting conditions as the instruments to which they relate.

(viii) Vesting equally on a quarterly basis beginning October 1, 2025 until July 1, 2026.

(ix) Vesting equally over three years on each anniversary date.

(x) Vesting equally on September 10, 2025, September 10, 2026 and September 10, 2027.

(xi) Vesting equally on April 1, 2026, April 1, 2027 and April 1, 2028.

No Options or Performance Units ("PUs") were granted as at September 30, 2025 and December 31, 2024. Certain members of the board of trustees of the Trust elected to be compensated fully or partially in Deferred Units ("DUs"), as described in the other operating expenses section below.

General and administrative expenses

General and administrative expenses include overhead costs incurred in the management of the business, such as, among others, depreciation of fixed assets, amortization of other intangibles, premises and office expenses. During the three and nine months ended September 30, 2025, the Trust recorded total general and administrative expenses of \$819 and \$1,016, respectively (2024 – \$80 and \$221, respectively), of which \$252 and \$252, respectively, were related to transitional services incurred as part of the internalization transaction, as described on page 5 of this MD&A and are not expected to recur (2024 – nil and nil, respectively).

Other operating expenses

Other operating expenses include fees paid to the board of trustees of the Trust and other ongoing operating expenses, including consulting, legal and audit fees required to operate our business, review the entity structure and improve governance processes in connection with internalization and the investigation into irregular expenses, as described on page 2 of this MD&A. During the three and nine months ended September 30, 2025, the Trust recorded total operating expenses of \$1,946 and \$10,490, respectively (2024 – \$4,818 and \$7,329, respectively).

A summary of the Trust's other operating expenses by nature is presented below.

	Three months ended September 30, 2025	Three months ended September 30, 2024	Nine months ended September 30, 2025	Nine months ended September 30, 2024
Board of trustees fees	\$ 416	\$ 124	\$ 1,271	\$ 800
Professional fees	664	4,034	7,204	4,881
Other expenses ⁽ⁱ⁾	866	660	2,015	1,648
Total other operating expenses	\$ 1,946	\$ 4,818	\$ 10,490	\$ 7,329

(i) Prior period figures have been adjusted to conform with the current period's classification.

Board of trustees fees

Certain members of the board of trustees of the Trust have elected to be compensated fully or partially in DUs under the Trust's Omnibus Equity Incentive Plan. The DUs granted pursuant to the election vest immediately and are settled in accordance with the established terms of the award agreement, but not earlier than the resignation or termination of the respective trustee from the board of trustees of the Trust. All DUs are credited with distribution equivalents in the form of additional DUs on each distribution payment date in respect of which normal distributions are paid on the Trust's Units. Such distribution equivalents are subject to the same vesting conditions as the instruments to which they relate. DUs are initially recognized at fair value and are subsequently remeasured at fair value on each reporting date, as described in note 3(p) to the Trust's 2024 consolidated financial statements.

During the three and nine months ended September 30, 2025, the Trust granted 15,105 and 47,985 DUs, respectively (2024 – 14,602 and 41,855, respectively), in lieu of cash compensation to trustees and 1,836 and 6,147 distribution equivalent Units, respectively (2024 – 1,400 and 3,382, respectively), in relation to the quarterly distributions. Board compensation expense for the three and nine months ended September 30, 2025 included \$370 and \$926, respectively (2024 – \$(88) and \$465, respectively), related to the issuance of DUs and the related distribution equivalents. During the three and nine months ended September 30, 2025, the Trust settled 38,485 DUs (2024 – nil). The fair value of the DUs vested but not settled was \$2,048 as at September 30, 2025 (December 31, 2024 – \$1,480) and was included in other current liabilities.

The increase in board compensation expense for the nine months ended September 30, 2025 compared to the same period in 2024 is primarily due to an increase in additional DUs granted to the board of trustees with the addition of an additional Trustee and additional committee fees of \$230 paid to the board of trustees.

Professional fees

For the three and nine months ended September 30, 2025, the Trust recorded total professional fees of \$664 and \$7,204, respectively (2024 – \$4,034 and \$4,881, respectively), related to professional services including audit, legal, tax, valuation and consulting. During the three and nine months ended September 30, 2025, the Trust incurred \$28 and \$2,087, respectively, to improve governance functions as a result of the investigation into irregular expenses charged to the Trust, as described on page 2 of this MD&A. During the three and nine months ended September 30, 2025, the Trust also incurred \$130 and \$4,202, respectively, in entity management legal expenses in relation to the internalization transaction, as described on page 5 of this MD&A. These additional governance and entity management fees related to the internalization and investigation are expected to be non-recurring.

Other expenses

Other expenses for the three and nine months ended September 30, 2025 were \$866 and \$2,015, respectively (2024 – \$660 and \$1,648, respectively), and included \$250 and \$763 in donations, respectively (2024 – \$258 and \$778, respectively), primarily related to the pledge agreement with the Mayo Clinic, as described on page 27 of this MD&A.

Gain (loss) on preferred securities

For the three and nine months ended September 30, 2025, the Trust recognized a net loss on preferred securities of nil and \$971, respectively (2024 – gain of nil and \$2,176, respectively). The loss is related to the change in the gross carrying amount of the redemption and cancellation of \$10,000 in face value of the 2024 Preferred Securities completed during the three months ended September 30, 2025. The gain recognized during 2024 is a result of the required accounting treatment applied to the refinancing of the 2023 Preferred Securities and 2023 Warrants (as defined herein) on April 23, 2024. The preferred securities are further described on page 22 of this MD&A.

Other loss

As described on page 2 of this MD&A, for the period from and including fiscal 2021 through June 30, 2024, the Trust was charged certain alleged consulting and other expenses that should not have been charged to the Trust. The Trust conducted an investigation and identified certain adjustments that were required to operating expenses, amortization of intangible royalty assets and the net book value of intangible royalty assets, with the impact of the corrections reflected in other loss. The Trust did not record an other loss during the three and nine months ended September 30, 2025 (2024 – nil and \$1,575, respectively).

Termination fee

On July 1, 2025, as part of the internalization transaction as described on page 5 of this MD&A, the Trust terminated the management agreement with the former external manager for \$48,000. As a result, during the three and nine months ended September 30, 2025, the Trust recorded a loss in the consolidated statements of net earnings (loss) and comprehensive earnings (loss) due to termination fees of \$48,000 (2024 – nil).

Income tax recovery

Related to the updated corporate structure of the Trust as a result of the internalization transaction as described on page 5 of this MD&A, certain subsidiaries of the Trust are now subject to income taxes. The Trust remains non-taxable, and the reported income tax recovery reflects taxes receivable by certain Trust subsidiaries. During the three and nine months ended September 30, 2025, the Trust recorded an income tax recovery of \$240 (2024 – nil).

Net unrealized gain (loss) on derivative instruments

The Trust uses interest rate swaps as a derivative financial instrument designated as a cash flow hedge to manage interest rate risk related to its credit facility, as described on page 22 of this MD&A. On August 31, 2023, the Trust entered into an interest rate swap agreement to fix the interest rate on a notional amount of \$100,000 of the credit facility. On June 10, 2025, to reflect changes resulting from amendments to the amended credit agreement, as described on page 21 of this MD&A, the Trust extended the maturity on its original interest rate swap to November 1, 2027. On June 10, 2025, the Trust also entered into a second interest rate swap with equivalent terms for an additional notional amount of \$50,000 to further manage interest rate risk on the credit facility. The Trust does not hold or use any derivative financial instruments for speculative trading purposes. The details of the interest rate swap are as follows:

Derivative Instruments	Maturity Date	Notional Value	Fair Value as at September 30, 2025	Fair Value as at December 31, 2024 ⁽ⁱ⁾
Interest rate swap	November 1, 2027	\$ 150,000	\$ (1,494)	\$ (425)

(i) The fair value as at December 31, 2024 is based on a notional amount of \$100,000 and a maturity date of March 31, 2026.

The Trust applies hedge accounting, as described in note 3(e) to the Trust's 2024 consolidated financial statements. During the three and nine months ended September 30, 2025, the Trust recognized a net unrealized fair value gain (loss) in other comprehensive earnings (loss) of \$184 and (\$972), respectively (2024 – loss of \$1,632 and \$207, respectively), as a result of the interest rate swap derivative instrument.

Weighted average number of Units

For the three and nine months ended September 30, 2025, the Trust generated basic and diluted net earnings (loss) per Unit of \$(1.05) and \$(1.06), respectively (2024 – \$(0.03) and \$(0.18), respectively). The weighted average number of Units outstanding for the purpose of calculating net earnings (loss) per Unit was as follows:

	Three months ended September 30, 2025	Three months ended September 30, 2024	Nine months ended September 30, 2025	Nine months ended September 30, 2024
Basic	55,351,226 Units	56,293,275 Units	55,944,375 Units	56,359,017 Units
Diluted	55,351,226 Units	56,293,275 Units	55,944,375 Units	56,359,017 Units

Summary of quarterly results

The following table provides a summary of the Trust's quarterly results, the distributions per Unit and the weighted average number of Units outstanding for the eight most recently completed quarters:

	2025				2024				2023
As at	September 30	June 30	March 31	December 31	September 30	June 30	March 31	December 31	
Total assets	\$ 909,046	\$ 967,257	\$ 962,045	\$ 984,867	\$ 884,079	\$ 874,067	\$ 901,270	\$ 833,159	
Credit facility and preferred securities ⁽ⁱ⁾	391,238	389,349	362,065	374,802	281,605	275,716	275,051	189,978	
Three months ended	September 30	June 30	March 31	December 31	September 30	June 30	March 31	December 31	
Total income	\$ 48,745	\$ 44,130	\$ 44,028	\$ 62,286	\$ 41,555	\$ 41,604	\$ 42,067	\$ 75,842	
Total expenses ⁽ⁱⁱ⁾	(58,845)	(42,783)	(45,780)	(55,285)	(43,247)	(45,149)	(47,796)	(53,134)	
Gain (loss) on preferred securities	—	(971)	—	—	—	2,176	—	—	
Other loss	—	—	—	—	—	(764)	(811)	(785)	
Termination fee	(48,000)	—	—	—	—	—	—	—	
Income tax recovery	\$ 240	—	—	—	—	—	—	—	
Net earnings (loss)	\$ (57,860)	\$ 376	\$ (1,752)	\$ 7,001	\$ (1,692)	\$ (2,133)	\$ (6,540)	\$ 21,923	
Net unrealized gain (loss) on derivative instruments	184	(1,076)	(80)	871	(1,632)	228	1,197	(1,741)	
Comprehensive earnings (loss)	\$ (57,676)	\$ (700)	\$ (1,832)	\$ 7,872	\$ (3,324)	\$ (1,905)	\$ (5,343)	\$ 20,182	
Net earnings (loss) per Unit									
Basic	\$ (1.05)	\$ 0.01	\$ (0.03)	\$ 0.12	\$ (0.03)	\$ (0.04)	\$ (0.12)	\$ 0.39	
Diluted	\$ (1.05)	\$ 0.01	\$ (0.03)	\$ 0.12	\$ (0.03)	\$ (0.04)	\$ (0.12)	\$ 0.39	
Distributions per Unit ⁽ⁱⁱⁱ⁾									
Cash	\$ 0.1000	\$ 0.1000	\$ 0.1000	\$ 0.0850	\$ 0.0850	\$ 0.0850	\$ 0.0850	\$ 0.3412	
Unit ^(iv)	n/a	n/a	n/a	\$ 0.0237	n/a	n/a	n/a	\$ 0.7640	
Weighted average number of Units									
Basic	55,351,226	55,685,363	56,307,817	56,282,403	56,293,275	56,426,259	56,358,240	56,332,607	
Diluted	55,351,226	55,685,363	56,307,817	56,678,956	56,293,275	56,426,259	56,358,240	56,464,102	

(i) Credit facility and preferred securities summary figures include only the non-current portion of the liabilities.

(ii) Total expenses for the fourth quarter of 2023 include performance fees of \$5,918 related to the milestone royalty income earned on Orserdu I, Orserdu II and Vonjo II.

(iii) Represents distributions declared during the period.

(iv) On December 20, 2024, the board of trustees of the Trust declared a special Unit distribution of \$0.0237 per Unit, totaling \$1,334 to Unitholders of record as at December 31, 2024, which was issued on December 31, 2024. On December 20, 2023, the board of trustees of the Trust declared a special Unit distribution of \$0.7640 per Unit, totaling \$43,058 to Unitholders of record as at December 31, 2023, which was issued on December 31, 2023. Immediately following the special Unit distribution, Units of the Trust were consolidated such that, after each consolidation, each Unitholder held the same number of Units as were held by the Unitholder immediately before the special Unit distribution.

FINANCIAL REVIEW: NON-GAAP FINANCIAL MEASURES

The Trust reports certain non-GAAP financial measures, including Total Cash Receipts, Normalized Total Cash Receipts, Total Cash Royalty Receipts and Adjusted EBITDA. The Trust also reports certain non-GAAP ratios, including Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit. These measures and ratios are not standardized financial measures under IFRS Accounting Standards as issued by the IASB and might not be comparable to similar financial measures disclosed by other issuers.

Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts

Total Cash Receipts refers to Total Cash Royalty Receipts plus cash receipts from all products. Total Cash Receipts includes cash receipts from interest as well as non-recurring cash receipts.

Total Cash Royalty Receipts refers to aggregate cash royalty receipts and milestone royalty receipts from our portfolio of royalty assets and forms part of Total Cash Receipts. Because of the lag between when we record royalty income and receive the corresponding cash payments on our royalties and milestones, we believe Total Cash Receipts and Total Cash Royalty Receipts are useful measures when evaluating our operations, as they represent actual cash generated in respect of all royalty assets held during a period. We also present Normalized Total Cash Receipts, which refers to Total Cash Receipts adjusted to remove cash receipts that are not expected to recur in the normal course of our operations. We believe that Normalized Total Cash Receipts will assist readers in evaluating the period-over-period performance of our royalty portfolio since Normalized Total Cash Receipts only includes cash receipts generated by royalties and other amounts payable pursuant to the terms of our royalty assets. There were no adjustments required to normalize cash receipts for the nine months ended September 30, 2025 and 2024.

	Cash Receipts			% Change	Cash Receipts			% Change
	Three months ended September 30, 2025	Three months ended September 30, 2024			Nine months ended September 30, 2025	Nine months ended September 30, 2024		
Royalty Assets								
Casgevvy	\$ —	\$ —	n/a		\$ 5,000	\$ —	n/a	
Empaveli/Syfovre	1,715	1,716	— %		2,987	4,291	(30)%	
Eylea I	1,245	1,442	(14)%		3,925	4,170	(6)%	
Eylea II	268	312	(14)%		847	902	(6)%	
Natpara	385	439	(12)%		886	1,702	(48)%	
Omidria	8,314	9,580	(13)%		25,301	29,401	(14)%	
Oracea	1,175	1,463	(20)%		3,755	5,799	(35)%	
Orserdu I ⁽ⁱ⁾	8,110	6,462	26 %		23,030	19,797	16 %	
Orserdu II ⁽ⁱ⁾	8,769	4,742	85 %		38,098	31,913	19 %	
Rydapt ⁽ⁱⁱ⁾	813	603	35 %		2,749	4,779	(42)%	
Spinraza	3,727	3,954	(6)%		11,470	11,069	4 %	
Vonjo I	2,890	3,053	(5)%		8,538	8,842	(3)%	
Vonjo II ⁽ⁱ⁾	623	650	(4)%		1,974	6,870	(71)%	
Xenpozyme	—	—	n/a		1,913	662	189 %	
Xolair	3,808	3,011	26 %		8,343	7,123	17 %	
Zejula	1,228	1,053	17 %		3,280	2,947	11 %	
Zytiga	—	—	n/a		2,230	3,546	(37)%	
Other Products ⁽ⁱⁱⁱ⁾	575	441	30 %		1,461	1,580	(8)%	
Total Cash Royalty Receipts, Cash Receipts and Normalized Cash Receipts	\$ 43,645	\$ 38,921	12 %		\$ 145,787	\$ 145,393	0.3 %	

(i) Cash receipts for Orserdu II and Orserdu I for the nine months ended September 30, 2025 include \$17,593 and \$633, respectively, for reclamation of previous royalty deductions, as described on page 4 of this MD&A. Cash receipts for the nine months ended September 30, 2024 include milestone royalty receipts of \$2,104 from Orserdu I, \$18,939 from Orserdu II and \$5,000 from Vonjo II received in Q1 2024.

(ii) Cash receipts for the nine months ended September 30, 2024 include \$1,000 in additional cash receipts related to a one-time payment received in Q1 2024.

(iii) Other Products includes royalty income from certain other intangible royalty assets as well as intangible royalty assets which are fully amortized and, where applicable, the entitlements to which have generally expired. Comparative figures for royalty assets Simponi, Stelara and Ilaris are included in Other Products.

Q3 Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts

Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts during the three months ended September 30, 2025 increased by \$4,724 or 12% compared to the same period in 2024. The increase was primarily driven by (i) the increase in Orserdu I and Orserdu II due to growing sales and removal of certain gross-to-net deductions previously incurred on Orserdu II, as described on page 4 of this MD&A; and (ii) the increased royalties on Xolair due to its growth following its launch for the food allergy indication. The increase in cash royalty receipts was partially offset by (i) a decline in Omidria royalty receipts due to declining sales volume; and (ii) increased competition and generic entrance into the market impacting the sales of Oracea.

Year-to-Date Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts

Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts during the nine months ended September 30, 2025 increased by \$394 or 0.3% compared to the same period in 2024. The increase was primarily driven by (i) the Orserdu II milestone obligation that was met in Q4 2024, which resulted in the reclamation of previously incurred royalty deductions, which were received during the nine months ended September 30, 2025 for \$15,745; (ii) the additional Xenpozyme royalty stream which earned its first cash receipt in 2025; (iii) the increased royalties on Xolair due to its growth following its launch for the food allergy indication and (iv) the additional receipts earned from the Casgevy asset, not owned in the prior period. The increase in cash royalty receipts was partially offset by (i) the Empaveli annual royalty cap being met in Q1 2025 based on 2024 annual sales; as no such receipts for Empaveli related to Q1 and Q2 2025 were received on the larger Empaveli royalty stream, this royalty cap resets annually; (ii) a decline in Omidria royalty receipts due to lower sales volume; (iii) the absence of milestone royalty receipts received during the nine months ended September 30, 2024 of \$26,043 related to Orserdu I, Orserdu II and Vonjo II; (iv) increased competition and generic entrance into the market impacting the sales of Oracea; (v) a one-time payment of \$1,000 related to Rydapt in 2024 combined with the expected contractual step-down in royalty entitlement for Rydapt, based on a cumulative sales threshold condition being met in Q3 2024; and (vi) the expected impact of increased competition on the sales of Zytiga due to generic entrance in the European market.

Cash Receipt Reconciliation

The reconciliation of Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts to the most directly comparable measures calculated in accordance with IFRS Accounting Standards as issued by the IASB is presented below. The Trust reconciles Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts to total income. Total income represents the sum of royalty income, change in fair value of financial royalty assets, unrealized gains on marketable securities and other interest income. Reconciling total income to Total Cash Receipts results in the subtraction of other interest income, net change in royalties receivable, net change in financial royalty assets, non-cash royalty income and non-cash interest and the addition of acquired royalties receivable.

When reconciling to Normalized Total Cash Receipts, we further subtract cash receipts not expected to recur, if any.

When reconciling to Total Cash Royalty Receipts, there is a corresponding subtraction to interest and other income on the loan receivable and an addition of non-cash interest and other income on the loan receivable and premiums for prepayment of loan receivable, since Total Cash Royalty Receipts is a measure of the Trust's cash royalty receipts from all products, excluding income from the Trust's debt instruments and cash receipts not expected to recur. For the purposes of complying with equal prominence requirements of applicable securities laws relating to non-GAAP financial measures, the Trust refers to total income when referring to Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts.

	Three months ended September 30, 2025	Three months ended September 30, 2024	Nine months ended September 30, 2025	Nine months ended September 30, 2024
Total income	\$ 48,745	\$ 41,555	\$ 136,903	\$ 125,226
[-] Other interest income	(253)	(596)	(907)	(1,895)
[-] Unrealized gain on marketable securities	(435)	—	(1,855)	—
[+] Royalties receivable, beginning of period	49,647	43,542	62,362	64,082
[-] Royalties receivable, end of period	(52,886)	(45,580)	(52,886)	(45,580)
[+] Financial royalty assets, beginning of period	54,184	—	57,527	—
[-] Financial royalty assets, end of period	(55,357)	—	(55,357)	—
[+] Acquired royalties receivable ⁽ⁱ⁾	—	—	—	3,560
[=] Total Cash Receipts, Royalty Cash Receipts and Normalized Cash Receipts	\$ 43,645	\$ 38,921	\$ 145,787	\$ 145,393

(i) Acquired royalties receivable represent the Trust's royalty entitlement to sales occurring prior to the completion of the royalty transactions.

Adjusted EBITDA

We believe Adjusted EBITDA provides meaningful information about our operating cash flows as it eliminates the effects of other non-cash expenses and accruals and income and expenses not expected to recur that have been recorded on the statements of net earnings (loss) and comprehensive earnings (loss). We refer to EBITDA when reconciling our net earnings (loss) and comprehensive earnings (loss) to Adjusted EBITDA, but we do not use EBITDA as a measure of our performance.

The reconciliation of Adjusted EBITDA to its most directly comparable measures calculated in accordance with IFRS Accounting Standards as issued by the IASB is presented below.

	Three months ended September 30, 2025	Three months ended September 30, 2024	Nine months ended September 30, 2025	Nine months ended September 30, 2024
Comprehensive earnings (loss)	\$ (57,676)	\$ (3,324)	\$ (60,208)	\$ (10,572)
[+] Amortization of intangible royalty assets	26,326	26,098	75,822	76,823
[+] Impairment of intangible royalty assets	13,691	901	13,691	6,101
[+] Depreciation of fixed assets and other intangible assets	136	—	136	—
[–] Income tax recovery	(240)	—	(240)	—
[–] Other interest income	(253)	(596)	(907)	(1,895)
[+] Interest expense	10,252	8,377	28,887	25,416
EBITDA	(7,764)	31,456	57,181	95,873
[+] Royalties receivable, beginning of period	49,647	43,542	62,362	64,082
[–] Royalties receivable, end of period	(52,886)	(45,580)	(52,886)	(45,580)
[–] Performance fees payable, beginning of period	—	—	(1,665)	(5,918)
[+] Performance fees payable, end of period	—	—	—	—
[+] Financial royalty assets, beginning of period	54,184	—	57,527	—
[–] Financial royalty assets, end of period	(55,357)	—	(55,357)	—
[–] Unrealized gain (loss) on marketable securities	(435)	—	(1,855)	—
[+] Acquired royalties receivable ⁽ⁱ⁾	—	—	—	3,560
[+] Unit-based compensation	1,150	347	2,580	7,589
[+] Board of trustees' unit-based compensation ⁽ⁱⁱ⁾	370	(87)	926	465
[+] (Gain) loss on preferred securities	—	—	971	(2,176)
[+] Termination fee ⁽ⁱⁱⁱ⁾	48,000	—	48,000	—
[+] Other loss	—	—	—	1,575
[+] Net unrealized loss (gain) on derivative instruments	(184)	1,632	972	207
[=] Adjusted EBITDA	36,725	31,310	118,756	119,677

(i) Acquired royalties receivable represent the Trust's royalty entitlements prior to the completion of the royalty transactions.

(ii) Certain members of the board of trustees of the Trust elected to be compensated fully or partially in DUs under the Trust's Omnibus Equity Incentive Plan, as described on page 13 of this MD&A.

(iii) For the three and nine months ended September 30, 2025 the Trust paid a termination fee as part of the internalization of its former external manager. The internalization is described further on page 5 of this MD&A.

Adjusted EBITDA during the three months ended September 30, 2025 was \$36,725, representing an increase of \$5,415 or 17% compared to the same period in 2024. The increase is primarily attributed to higher royalty income in the period compared to the prior period, as described further on page 8 of this MD&A.

Adjusted EBITDA for the nine months ended September 30, 2025 was \$118,756, representing a decrease of \$921 or 1%. The decrease can be attributed primarily to the larger net movement in the royalties receivable balance in the prior year. Despite an overall increase in royalty income recognized in the period compared to the prior period, overall expenses for the period were higher than for the similar period last year due to the non-recurring expenses detailed below.

The table below details non-recurring expenses incurred during the three and nine months ended September 30, 2025 and 2024.

	Three months ended September 30, 2025	Three months ended September 30, 2024	Nine months ended September 30, 2025	Nine months ended September 30, 2024
Non-recurring expenses				
Organizational restructuring costs ⁽ⁱ⁾	\$ 709	\$ —	\$ 709	\$ —
Transition fees ⁽ⁱⁱ⁾	252	—	252	—
Special committee fees ⁽ⁱⁱⁱ⁾	—	175	230	175
Professional fees related to improving governance ^(iv)	28	2,716	2,087	2,716
Professional fees related to internalization ^(iv)	130	20	4,202	20
Total non-recurring expenses	\$ 1,119	\$ 2,911	\$ 7,480	\$ 2,911

(i) Included in compensation expense is a one-time organizational restructuring cost that is not expected to recur.

(ii) Transition fees are included in general and administrative expenses for services rendered during the transition from the former external manager as part of the internalization, as described on page 5 of this MD&A.

(iii) Included in board of trustee fees within other operating expenses were special committee costs related to the investigation and internalization.

(iv) Various professional fees were incurred by the Trust related to improving governance in the aftermath of the investigation of irregular expenses, as described on page 2 of this MD&A, and related to the internalization, as described on page 5 of this MD&A. These costs are included in professional fees within other operating expenses and are non-recurring by nature.

Adjusted EBITDA for the three and nine months ended September 30, 2025 would have been \$37,844 and \$126,236, respectively (2024 – \$34,221 and \$122,588, respectively), without these non-recurring expenses.

Adjusted EBITDA Margin

We believe that Adjusted EBITDA Margin is a useful supplemental measure to demonstrate the operating efficiency of our business on a cash basis.

The calculation of Adjusted EBITDA Margin is presented below.

	Three months ended September 30, 2025	Three months ended September 30, 2024	Nine months ended September 30, 2025	Nine months ended September 30, 2024
Adjusted EBITDA	\$ 36,725	\$ 31,310	\$ 118,756	\$ 119,677
[+] Normalized Total Cash Receipts	43,645	38,921	145,787	145,393
[=] Adjusted EBITDA Margin	84%	80%	81%	82%

As described earlier, Adjusted EBITDA for the three and nine months ended September 30, 2025 includes non-recurring expenses of \$1,119 and \$7,480, respectively (2024 – \$2,911 and \$2,911, respectively). Without these non-recurring expenses, Adjusted EBITDA margin would have been 87% for both the three and nine months ended September 30, 2025 (2024 – 88% and 84%, respectively).

Adjusted Cash Earnings per Unit

We believe that Adjusted Cash Earnings per Unit provides meaningful information about our performance as it provides a measure of the cash generated by our assets on a per Unit basis, excluding cash earnings that are not expected to recur.

The calculation of Adjusted Cash Earnings per Unit is presented below.

	Three months ended September 30, 2025	Three months ended September 30, 2024	Nine months ended September 30, 2025	Nine months ended September 30, 2024
Comprehensive earnings (loss)	\$ (57,676)	\$ (3,324)	\$ (60,208)	\$ (10,572)
[+] Amortization of intangible royalty assets	26,326	26,098	75,822	76,823
[+] Non-cash general and administrative expenses ⁽ⁱ⁾	136	—	136	—
[+] Impairment of intangible royalty assets	13,691	901	13,691	6,101
[+] Unrealized loss (gain) on marketable securities	(435)	—	(1,855)	—
[+] Unit-based compensation	1,150	347	2,580	7,589
[+] Board of trustees' unit-based compensation ⁽ⁱⁱ⁾	370	(87)	926	465
[–] Change in fair value of financial royalty assets	(1,173)	—	(2,830)	—
[+] Cash receipts on financial royalty assets	—	—	5,000	—
[–] (Gain) Loss on preferred securities	—	—	971	(2,176)
[+] Other loss	—	—	—	1,575
[–] Termination fee ⁽ⁱⁱⁱ⁾	48,000	—	48,000	—
[+] Net unrealized loss (gain) on derivative instruments	(184)	1,632	972	207
Adjusted Cash Earnings (Loss)	\$ 30,205	\$ 25,567	\$ 83,205	\$ 80,012
[+] Weighted average number of Units – basic	55,351,226	56,293,275	55,944,375	56,359,017
[=] Adjusted Cash Earnings (Loss) per Unit – basic	\$ 0.55	\$ 0.45	\$ 1.49	\$ 1.42
[+] Weighted average number of Units – diluted	55,351,226	56,293,275	55,944,375	56,359,017
[=] Adjusted Cash Earnings (Loss) per Unit – diluted	\$ 0.55	\$ 0.45	\$ 1.49	\$ 1.42

(i) Included in general and administrative expenses are non-cash expenses related to the depreciation of fixed assets and amortization of other intangible assets.

(ii) Certain members of the board of trustees of the Trust elected to be compensated fully or partially in DUs under the Trust's Omnibus Equity Incentive Plan, as described on page 13 of this MD&A.

(iii) For the three and nine months ended September 30, 2025 the Trust paid a termination fee as part of the internalization of its former external manager. The internalization is described further on page 5 of this MD&A.

Adjusted Cash Earnings (Loss) and Adjusted Cash Earnings (Loss) per Unit, basic and diluted, for the three months ended September 30, 2025 were \$30,205 and \$0.55, respectively, compared to \$25,567 and \$0.45, respectively, for the same period in 2024, representing an increase of \$4,638 or \$0.10 per Unit. For the nine months ended September 30, 2025 Adjusted Cash Earnings (Loss) and Basic Adjusted Cash Earnings (Loss) per Unit, basic and diluted, were \$83,205 and \$1.49, respectively, compared to \$80,012 and \$1.42, respectively, for the same period in 2024, representing an increase of \$3,193 or \$0.07 per Unit.

FINANCIAL REVIEW: FINANCIAL POSITION

As at September 30, 2025, the Trust had consolidated total assets of \$909,046 (December 31, 2024 – \$984,867) and consolidated total liabilities of \$471,946 (December 31, 2024 – \$457,336). The following table presents the components of consolidated total assets and total liabilities as at September 30, 2025 and December 31, 2024, followed by a discussion of significant categories of assets and liabilities.

		As at September 30, 2025		As at December 31, 2024
Assets				
Cash and cash equivalents	\$	35,608	\$	36,502
Royalties receivable		52,886		62,362
Other current assets		1,313		303
Current assets		89,807		99,167
Intangible royalty assets, net of accumulated amortization		756,423		823,936
Financial royalty assets		55,357		57,527
Investment in marketable securities		6,090		4,235
Other non-current assets		1,369		2
Non-current assets		819,239		885,700
Total assets	\$	909,046	\$	984,867
Liabilities				
Accounts payable and accrued liabilities	\$	8,006	\$	4,821
Distributions payable to Unitholders		5,515		4,786
Performance fees payable		—		1,665
Current portion of credit facility		59,588		56,888
Current portion of unit-based compensation liability		1,386		2,093
Other current liabilities		4,265		11,616
Current liabilities		78,760		81,869
Credit facility		285,488		263,865
Preferred securities		105,750		110,937
Derivative instruments		1,494		425
Unit-based compensation liability		78		240
Other non-current liabilities		376		—
Total liabilities	\$	471,946	\$	457,336

Intangible royalty assets

As at September 30, 2025, the net book value of our intangible royalty assets was \$756,423 (December 31, 2024 – \$823,936), net of accumulated amortization and impairment of \$351,791 (December 31, 2024 – \$304,008). During the nine months ended September 30, 2025, the Trust recorded additions to the cost of its intangible royalty assets of \$22,000 (December 31, 2024 – \$237,616) related to the Ekterly one-time optional payment, as described on page 6 of this MD&A. The Trust also wrote off the cost, related accumulated amortization and accumulated impairment of \$41,730 related to the fully amortized royalty assets in accordance with its amortization policy, as described in note 3 to the Trust's 2024 consolidated financial statements (December 31, 2024 – \$1,475). There was no change to the net book value of the intangible royalty assets as a result of these write-offs.

During the three and nine months ended September 30, 2025, the Trust recognized an impairment loss of \$13,691 (2024 – nil) related to the Vonjo II royalty asset, as described on page 4 of this MD&A. The impairment loss is recognized in the consolidated statements of net earnings and comprehensive earnings. The recoverable amount of Vonjo II is \$39,015 as at September 30, 2025 and is based on a value in use calculation. The Trust determined the recoverable amount of the asset using a discounted cash flow model based on forecasted royalties and a discount rate of 8%. The net book value of the asset prior to recognizing an impairment exceeded the recoverable amount and the difference of \$13,691 was recognized as an impairment loss.

During the year ended December 31, 2024, the Trust recognized an impairment loss of \$15,787 related to the Oracea royalty asset, as described on page 4 of this MD&A. The impairment loss is recognized in the consolidated statements of net earnings and comprehensive earnings.

Financial royalty assets

As at September 30, 2025, the Trust had financial royalty assets of \$55,357 (December 31, 2024 – \$57,527), representing the fair value of the Casgevy royalty asset. During the nine months ended September 30, 2025 the Trust had (i) cash receipts of \$5,000; (ii) changes in fair value due to the passage of time of \$5,748; (iii) changes in fair value due to changes in the risk-free rate of \$768; and (iv) changes in fair value due to changes in the expected timing of future cash flows of \$(3,686). The change in timing of future cash flows relates to a delay in the expected receipt date of the contingent payment, as described on page 7 of this MD&A. Despite the delay there is no change in the Trust's anticipated likelihood of receipt.

Distributions payable to Unitholders

As at September 30, 2025, the Trust had distributions payable of \$5,515, representing a quarterly cash distribution declared on August 13, 2025 to Unitholders of record as at September 30, 2025, which was paid on October 20, 2025.

As at December 31, 2024, the Trust had distributions payable of \$4,786, representing a quarterly cash distribution declared on November 6, 2024 to Unitholders of record as at December 31, 2024, which was paid on January 20, 2025.

The Trust pays a quarterly distribution in accordance with its distribution policy, as described in note 8 to the consolidated financial statements.

Subsequent to September 30, 2025, the board of trustees of the Trust declared a quarterly distribution of \$0.10 per Unit to Unitholders of record as at December 31, 2025, payable on January 20, 2026.

Credit facility and preferred securities

Credit facility

Our amended and restated credit agreement (the "**amended credit agreement**"), dated as of April 20, 2022, as further amended from time to time, is composed of (i) a senior secured revolving acquisition credit facility (the "**acquisition credit facility**"); (ii) a senior secured revolving working capital credit facility (the "**working capital credit facility**"); and (iii) a delayed draw term loan (the "**term credit facility**", collectively, the "**credit facility**").

On November 1, 2024, the Trust increased the total credit available under its credit facility to \$631,625, composed of (i) a \$525,000 acquisition credit facility; (ii) a \$81,625 term credit facility; and (iii) a \$25,000 working capital credit facility. The Trust also extended the maturity date of the amended credit agreement from October 31, 2026 to November 1, 2027, which may be extended by one-year increments subject to obtaining approval from the lenders. As part of the amendment, the interest rate for drawings on the amended credit facility was also revised to SOFR plus (i) a margin which may vary from 1.75% to 2.50% based on the Trust's leverage ratio; and (ii) a margin of 0.10% to 0.25% based on the term of the borrowing. The range of standby fees was also revised to 0.35% to 0.50% based on the Trust's leverage ratio. All other material terms of the amended credit agreement remain unchanged.

On May 12, 2025, the Trust further revised its amended credit agreement to reallocate \$25,000 of the acquisition credit facility to the working capital credit facility, increasing it to \$50,000. The credit available for investment remains unchanged as the working capital credit facility can be used for investment purposes. Furthermore, the interest rate on the amended credit agreement was revised to SOFR plus (i) a margin which may vary from 1.75% to 2.50% based on the Trust's leverage ratio; and (ii) a margin of 0.10%. All other material terms of the amended credit agreement remain unchanged.

Subsequent to September 30, 2025, the Trust amended its amended credit agreement to, among other things, convert and merge the term credit facility into the acquisition credit facility. The total credit available under the acquisition credit facility increased by \$70,000 and the outstanding amount under the acquisition credit facility increased by an amount corresponding to the outstanding amount under the term credit facility as at October 3, 2025, which was \$63,250. This increased the total credit available under the acquisition credit facility to \$570,000. The Trust also extended the maturity date of the amended credit agreement by two years to October 3, 2029, which may be extended by one-year increments subject to lender approval. Certain other terms were also adjusted to provide the Trust with greater flexibility. All other material terms of the amended credit agreement remain unchanged.

Interest payments are due on a quarterly basis and mandatory principal repayments totaling 3.75% of a predetermined reference amount are due on a quarterly basis for the acquisition credit facility and term credit facility. Principal repayments on the working capital credit facility are due on maturity. Principal repayments do not result in a corresponding decrease in the borrowing capacity under the acquisition credit facility and working capital credit facility. Principal repayments result in a corresponding cancellation in the borrowing capacity under the term credit facility; as a result there is no remaining available credit under the term credit facility as at September 30, 2025 (December 31, 2024 – nil).

The carrying amount of the Trust's credit facility is presented below:

	As at September 30, 2025			As at December 31, 2024	
	Total Available Credit	Remaining Available Credit	Balance Outstanding	Balance Outstanding	
Acquisition credit facility	\$ 500,000	\$ 264,437	\$ 235,563	\$ 247,122	
Term credit facility	63,250	—	63,250	77,031	
Working capital credit facility	50,000	1,000	49,000	—	
	\$ 613,250	\$ 265,437	\$ 347,813	\$ 324,153	
Deferred transaction costs, net of amortization	n/a	n/a	(2,737)	(3,400)	
Total	\$ 613,250	\$ 265,437	\$ 345,076	\$ 320,753	
Current portion of credit facility			\$ 59,588	\$ 56,888	
Long-term portion of credit facility			285,488	263,865	
Total			\$ 345,076	\$ 320,753	

The increase in the carrying amount of the credit facility is attributed to (i) a drawing made on June 30, 2025 of \$49,000 from the working capital credit facility to fund the internalization of the Trust's investment management function and terminate the management agreement on July 1, 2025, as described on page 5 of this MD&A; and (ii) a drawing made on July 9, 2025 of \$18,000 from the acquisition credit facility to partially fund the Ekterly one-time optional payment, as described on page 6 of this MD&A. The remaining amount of the transaction was funded by the Trust's existing cash and cash flows.

Subsequent to September 30, 2025, the Trust drew \$50,000 from its acquisition credit facility to partially fund the veligrotug and VRDN-003 transaction, as further described on page 6 of this MD&A.

During the nine months ended September 30, 2025, the Trust made total mandatory credit facility repayments of \$43,341 (2024 – \$51,937).

The following table presents expected principal repayments to be made until the maturity of the credit facility as at September 30, 2025:

	Total
Remainder of: 2025	\$ 14,897
Full year: 2026	59,588
Full year: 2027	273,328
	\$ 347,813

The Trust is subject to certain financial as well as customary non-financial covenants under the amended credit agreement. Certain compliance requirements have also been revised as part of the amended credit agreement. Substantially all of the assets of the Trust are pledged as collateral under the amended credit agreement. As at September 30, 2025, the Trust was in compliance with all covenant requirements under the amended credit agreement.

Interest Rate Swap

On August 31, 2023, the Trust entered into an interest rate swap agreement to fix the interest rate on a notional amount of \$100,000 of the credit facility. On June 10, 2025, to reflect changes resulting from amendments to the amended credit agreement, the Trust extended the maturity on its original interest rate swap to November 1, 2027. On June 10, 2025 the Trust also entered into a second interest rate swap with equivalent terms for an additional notional amount of \$50,000. Under the agreements, the Trust pays a fixed rate and in exchange receives a SOFR interest rate, offsetting the floating component on a portion of the credit facility.

During the three and nine months ended September 30, 2025, the Trust recorded a reduction in interest due to the interest rate swaps of \$18 and \$57, respectively (2024 – \$178 and \$531, respectively).

Preferred Securities

On February 8, 2023, the Trust completed a private placement of securities (the "**2023 Private Placement**") to a group of investors, the proceeds from which were used to repay amounts owing under the Trust's amended credit agreement. The 2023 Private Placement provided gross proceeds of \$95,000 to the Trust through the sale of \$95,000 principal amount of Series A Preferred Securities, \$19,760 principal amount of Series B Preferred Securities (collectively, the "**2023 Preferred Securities**") and the issuance of 6,369,180 warrants (the "**2023 Warrants**"). The 2023 Warrants are further described on page 26 of this MD&A. The 2023 Preferred Securities were unsecured, subordinated debt securities of the Trust. The 2023 Preferred Securities paid cash interest at a rate of 7.04% per annum on the principal amount of the 2023 Preferred Securities, payable semi-annually on June 30 and December 31 of each year.

The Series A Preferred Securities had a maturity date of February 8, 2073 and the Series B Preferred Securities had a maturity date of December 27, 2027. The Series A Preferred Securities were redeemable at par, at the option of the Trust, at any time from and after December 27, 2027. The 2023 Preferred Securities were not redeemable by the Trust prior to December 27, 2027, except in the event of a change of control of the Trust, in which case the 2023 Preferred Securities were subject to a mandatory redemption.

The Trust initially recognized the 2023 Preferred Securities using a discount rate of 12.77%, which is indicative of the fair market value of the 2023 Preferred Securities at the time of issuance. The carrying amount of the 2023 Preferred Securities was being accreted to its par value up until December 27, 2027, which is the date at which the Series A Preferred Securities could be redeemed by the Trust and the stated maturity date for the Series B Preferred Securities. Deferred transaction costs of \$3,171 were initially recognized and were being amortized using the effective interest rate method over the same period as the 2023 Preferred Securities accretion period.

On April 23, 2024 the Trust completed a refinancing of the 2023 Preferred Securities and the 2023 Warrants. As a result of the refinancing, holders of the 2023 Preferred Securities and 2023 Warrants received gross proceeds of \$20,441 through the sale of \$135,202 principal amount of new 2024 Preferred Securities and 1,749,996 new warrants (the "**2024 Warrants**"), having an exercise price representing a 20% premium to the five-day volume-weighted average price of the Trust's Units. The 2023 Preferred Securities were canceled and the 2023 Warrants were redeemed upon completion of the refinancing, with holders entitled to receive accrued and unpaid interest on the 2023 Preferred Securities up to and excluding such date. The redemption of the in-the-money 2023 Warrants addressed potential dilution concerns of existing Unitholders.

The 2024 Preferred Securities are unsecured, subordinated debt securities of the Trust and have a principal amount of \$135,202, maturing on April 23, 2074. The 2024 Preferred Securities initially pay cash interest at a rate of 7.50% per annum on the principal amount, payable semi-annually on April 30 and October 31 of each year. The 2024 Preferred Securities are not redeemable by the Trust prior to April 30, 2029, except in the event of a change in control of the Trust. The Trust determined that the modification of terms under the refinancing transaction is not substantial in nature by comparing the discounted cash flows under the 2024 Preferred Securities and the 2023 Preferred Securities using the original discount rate of 12.77%. A gain on debt refinancing of \$2,176 was recorded as a result of this transaction. Additional deferred transaction costs of \$501 were recognized related to the preferred securities refinancing and will be amortized using the effective interest rate method up to April 30, 2029, the date at which the 2024 Preferred Securities could be redeemed by the Trust.

On June 18, 2025, the Trust entered into an agreement with a private placement investor to partially redeem and cancel \$10,000 in face value of the 2024 Preferred Securities for \$9,500. The Trust paid outstanding accrued interest on the \$10,000 face value up to and including June 18, 2025, the date of the transaction. The terms of the remaining 2024 Preferred Securities remain unchanged. During the nine months ended September 30, 2025, the Trust recorded a loss of \$971 related to the changes in the gross carrying amount of the partial redemption.

The interest rate on the 2024 Preferred Securities will increase to 10% per annum if any of the 2024 Preferred Securities are outstanding on April 30, 2029, and will be subject to an annual increase of 1.5% per annum if any of the 2024 Preferred Securities remain outstanding on each one year anniversary of such date, up to a specified cap.

The carrying amount of the Preferred Securities is presented below.

		As at September 30, 2025	As at December 31, 2024
Series C	\$	107,877	\$ 113,515
Deferred transaction costs, net of amortization		(2,127)	(2,578)
Total	\$	105,750	\$ 110,937

FINANCIAL REVIEW: CASH FLOWS

The Trust generated the following cash flows during the nine months ended September 30, 2025 and 2024.

		Nine months ended September 30, 2025		Nine months ended September 30, 2024
Cash and cash equivalents – beginning of period	\$	36,502	\$	62,835
Cash provided by operating activities		64,601		117,760
Cash provided by (used in) financing activities		(37,495)		38,141
Cash used in investing activities		(28,000)		(129,330)
Change in cash and cash equivalents		(894)		26,571
Cash and cash equivalents – end of period	\$	35,608	\$	89,406

During the nine months ended September 30, 2025, the Trust generated cash flows provided by operating activities of \$64,601, \$53,159 lower compared to the same period the previous year. The decrease was primarily due to the \$48,000 termination fee paid by the Trust as part of the internalization transaction, as described on page 5 of this MD&A, higher non-recurring expenses incurred of \$7,480 compared to \$2,911 in the same period the previous year, and compensation expenses being incurred in the nine months ended September 30, 2025 compared to being incurred only in the three months ended September 30, 2024.

For the nine months ended September 30, 2025, the Trust used cash flows of \$37,495 from financing activities while generating \$38,141 in the same period the previous year, a difference of a \$75,636 increase in cash used. The increase is primarily due to lower drawings of \$70,000 on the credit facility during the nine months ended September 30, 2025. The Trust drew \$67,000 from its credit facility during the nine months ended September 30, 2025, using \$49,000 to fund the termination fee and the assets purchased in connection with the internalization transaction, as described on page 5 of this MD&A, and using \$18,000 to partially fund the Ekterly one-time optional payment of \$22,000 along with available cash, as described on page 6 of this MD&A. The Trust also used more available cash during the nine months ended September 30, 2025 than in the comparable period in the previous year. Available cash was also used to repay \$43,341 on the credit facility, to pay interest of \$22,106 on its credit facility and preferred securities, to pay cash distributions of \$15,967, to repurchase and cancel Units under its NCIB program for \$13,193, and to partially redeem \$10,000 face value of preferred securities for \$9,500.

For the nine months ended September 30, 2025, the Trust used cash flows of \$28,000 for investing activities, which was \$101,330 lower than cash used in the same period the previous year. The decrease was primarily due to lower levels of asset transactions in the current period. The Trust paid \$32,000 to fund the Orserdu II milestone of \$10,000 and to fund the Ekterly one-time optional payment of \$22,000, as described on page 6 of this MD&A. The Trust also used \$1,000 to fund the acquisition of certain relevant assets of its former external manager, as described on page 5 of this MD&A. Partially offsetting these uses of cash in investing activities was the receipt of \$5,000 for the annual license fees from the Casgevy financial royalty asset, as described on page 7 of this MD&A.

EQUITY

Authorized equity

The Trust's authorized equity capital consists of (i) an unlimited number of Units; and (ii) an unlimited number of Preferred Units, issuable in series. Issued and outstanding Units may be subdivided or consolidated from time to time by the Trust without notice to, or the approval of, the Unitholders.

Units

Each Unit represents a proportionate undivided beneficial ownership interest in the Trust, which entitles the holder to one vote, participation in distributions made by the Trust on a pro rata basis and, in the event of the termination or winding-up of the Trust, in the pro rata share of its net assets remaining after the satisfaction of all its liabilities. Units are discussed in further detail in note 8 to the consolidated financial statements. As at September 30, 2025, 55,149,552 (December 31, 2024 – 56,304,425) Units were outstanding at a cost of \$551,056 (December 31, 2024 – \$562,583).

The following table outlines the changes in the number of Units outstanding from December 31, 2023 to September 30, 2025:

	Units	Weighted Average Cost per Unit	Total Cost
Balance – December 31, 2023	56,358,240	n/a	\$ 561,503
Issuance of Units:			
Units issued on the settlement of vested Restricted Units	316,926	\$ 10.52	\$ 3,335
Repurchase and cancellation of Units – NCIB	(406,346)	\$ 9.64	\$ (3,917)
Balance – September 30, 2024	56,268,820	n/a	\$ 560,921
Issuance of Units:			
Units issued on the settlement of vested Restricted Units	35,605	\$ 9.21	\$ 328
Unit distributions to Unitholders	160,997	8.29	1,334
Consolidation of Units	(160,997)	n/a	n/a
Balance – December 31, 2024	56,304,425	n/a	\$ 562,583
Issuance of Units:			
Units issued on the settlement of vested Restricted Units	179,265	\$ 9.67	\$ 1,733
Units issued on the settlement of vested Deferred Units	17,759	\$ 9.10	\$ 162
Repurchase and cancellation of Units – NCIB	(1,351,897)	\$ 9.76	\$ (13,193)
Equity tax on share repurchases	n/a	n/a	\$ (229)
Balance – September 30, 2025	55,149,552	n/a	\$ 551,056

Settlement of vested Restricted Units

The following table outlines the Units issued upon settlement of vested RUs during the nine months ended September 30, 2025, the nine months ended September 30, 2024 and the three months ended December 31, 2024:

	Units Issued on Settlement of Restricted Units		
	Nine months ended September 30, 2025	Nine months ended September 30, 2024	Three months ended December 31, 2024
Restricted Units Grant Date:			
September 10, 2021	—	12,452	—
November 30, 2021	—	—	29,116
June 10, 2022	6,878	7,309	—
September 10, 2022	11,613	13,965	—
November 22, 2022	14,033	17,038	—
August 17, 2023	2,907	3,613	—
October 25, 2023	28,770	28,576	—
December 21, 2023	2,547	2,442	—
January 10, 2024	75,410	104,495	—
May 1, 2024	2,909	3,598	—
May 31, 2024	12,851	123,438	—
August 13, 2024	19,841	—	6,489
September 4, 2025	1,506	—	—
Total	179,265	316,926	35,605

The decrease in the number of Units issued upon the settlement of vested RUs during the nine months ended September 30, 2025 compared to the same period in 2024 is due in part to the timing of the vesting of the RUs granted in the previous year and the unit price at the time of vesting.

Settlement of Deferred Units

During the nine months ended September 30, 2025, the Trust issued 17,759 Units (2024 – nil) upon settlement of vested DUs, as described on page 13 of this MD&A.

Normal course issuer bid

From time to time, the market price of the Units of the Trust may not adequately reflect the value of the underlying assets of the Trust, and management wishes to take advantage of the market trading prices of its Units in those instances.

On November 13, 2023, the Trust was granted approval by the TSX to acquire, from time to time, if considered advisable, up to 3,280,195 Units of the Trust for cancellation between November 20, 2023 and November 19, 2024 (“**November 2023 NCIB**”) by the TSX. In connection with the November 2023 NCIB, the Trust established an AUPP whereby Units of the Trust may be repurchased at the discretion of a dealer to the AUPP using commercially reasonable efforts and subject to trading parameters defined in the AUPP.

On May 9, 2025, the Trust was granted approval for the May 2025 NCIB by the TSX. In connection with the May 2025 NCIB, the Trust established an AUPP whereby Units of the Trust may be repurchased at the discretion of a dealer to the AUPP using commercially reasonable efforts and subject to trading parameters defined in the AUPP.

During the nine months ended September 30, 2025, the Trust acquired and canceled 1,351,897 Units at an average price of \$9.76, totaling \$13,193. As at September 30, 2025, in aggregate, the Trust has acquired and canceled 4,515,406 Units at an average price per Unit of \$7.00, totaling \$31,620 under the NCIB Plans.

As at September 30, 2025, the Trust recorded an other current liability of \$2,000 representing the maximum amount that would be required to settle the AUPP in effect on September 30, 2025, with a corresponding decrease in other equity.

Warrants

In connection with the 2023 Private Placement, the Trust issued 6,369,180 Warrants to the 2023 Private Placement investors. Each 2023 Warrant entitled the holder thereof to acquire one Unit of the Trust for an exercise price of \$11.62 at any time until the expiry of the 2023 Warrants on February 8, 2028. The 2023 Warrant exercise price represented a 106% premium to the volume weighted average price of the Trust's Units for the 20 trading days ending February 7, 2023. The 2023 Warrants were not listed on any stock exchange, although the underlying Units of the Trust issuable pursuant to the 2023 Warrants are listed on the TSX. The 2023 Warrants were included in other equity reserves. Transaction costs associated with the issuance incurred in 2023 totaled \$79 and were recorded as a reduction in other equity reserves.

The fair value of the 2023 Warrants was estimated at \$2,229 on issuance date using the Black-Scholes valuation model. The assumptions used to determine the fair value of the 2023 Warrants include: (i) an exercise price of \$11.62; (ii) an average risk-free interest rate of 3.558%; (iii) an expected 2023 Warrant life of five years; (iv) an average expected volatility of 30%, estimated based on market data; and (v) an expected distribution yield of 5.579%.

On April 23, 2024 the Trust completed a refinancing of the 2023 Preferred Securities and the 2023 Warrants. As a result of the refinancing, the 2023 Warrants were redeemed for \$20,441 and 1,749,996 2024 Warrants were issued. Each 2024 Warrant entitles the holder thereof to acquire one Unit of the Trust for an exercise price of \$15.00 at any time until the expiry of the 2024 Warrants on April 23, 2029. The 2024 Warrant exercise price represents a 20% premium to the volume-weighted average price of the Trust's Units for the five trading days ending April 12, 2024. As a result of the refinancing, the number of warrants outstanding has reduced, thus reducing the potential impact of Unit dilution that would occur if the 2023 Warrants were exercised. Transaction costs associated with the issuance incurred in 2024 totaled \$137 and were recorded as a reduction in other equity reserves.

The fair value of the 2024 Warrants was estimated at \$4,322 on issuance date using the Black-Scholes valuation model. The assumptions used to determine the fair value of the 2024 Warrants include: (i) an exercise price of \$15.00; (ii) an average risk-free interest rate of 4.38%; (iii) a five-year term; (iv) an average expected volatility of 30.5%, estimated based on market data; and (v) an expected distribution yield of 3.35%.

As at September 30, 2025, the net value of the 2024 Warrants recognized in other equity reserves was \$4,106 (December 31, 2024 – \$4,106).

Distributions

The Trust pays quarterly distributions in accordance with its distribution policy, which is described in the Trust's most recent annual information form. The following table presents cash and Unit distributions made by the Trust during the nine months ended September 30, 2025 and year ended December 31, 2024:

	Record Date	Payment Date	Distribution per Unit	Total Distribution
2025				
Q1 2025 – Quarterly cash distribution	March 31, 2025	April 17, 2025	\$ 0.1000	\$ 5,631
Q2 2025 – Quarterly cash distribution	June 30, 2025	July 18, 2025	0.1000	5,550
Q3 2025 – Quarterly cash distribution	September 30, 2025	October 20, 2025	0.1000	5,515
Total			\$ 0.3000	\$ 16,696
2024				
Q1 2024 – Quarterly cash distribution	March 31, 2024	April 19, 2024	\$ 0.0850	\$ 4,790
Q2 2024 – Quarterly cash distribution	June 30, 2024	July 19, 2024	0.0850	4,795
Q3 2024 – Quarterly cash distribution	September 30, 2024	October 18, 2024	0.0850	4,783
Q4 2024 – Quarterly cash distribution	December 31, 2024	January 20, 2025	0.0850	4,786
Q4 2024 – Unit distribution ⁽ⁱ⁾	December 31, 2024	n/a	0.0237	1,334
Total			\$ 0.3637	\$ 20,488

(i) On December 20, 2024, the board of trustees of the Trust declared a special Unit distribution of \$0.0237 per Unit, totaling \$1,334 to Unitholders of record as at December 31, 2024, which was issued on December 31, 2024. Immediately following the special Unit distribution, Units of the Trust were consolidated such that, after each consolidation, each Unitholder held the same number of Units as were held by the Unitholder immediately before the special Unit distribution.

During the three and nine months ended September 30, 2025, the board of trustees of the Trust declared cash distributions totaling \$5,515 and \$16,696, respectively (2024 – \$4,783 and \$14,368, respectively).

Subsequent to September 30, 2025, the board of trustees of the Trust declared a quarterly cash distribution of \$0.10 per Unit to Unitholders of record as at December 31, 2025 and payable on January 20, 2026.

LIQUIDITY AND CAPITAL RESOURCES

As at September 30, 2025, the Trust's capital was \$1,011,068 (December 31, 2024 – \$1,004,573) and consisted of its Unitholders' capital of \$551,056 (December 31, 2024 – \$562,583), 2024 Preferred Securities, prior to the deduction of deferred transaction costs, net of amortization, of \$107,877 (December 31, 2024 – \$113,515), 2024 Warrants, prior to the deduction of deferred transaction costs of \$4,322 (December 31, 2024 – \$4,322) and amended credit facilities, prior to the deduction of deferred transaction costs, net of amortization, of \$347,813 (December 31, 2024 – \$324,153).

The Trust's objectives in managing capital are to:

- Build long-term value for its Unitholders;
- Maintain optimal liquidity for pursuing acquisitions, meeting its obligations and making distributions to Unitholders;
- Achieve reasonable return on capital and control the risk and exposure associated with capital investments; and
- Maintain an optimal capital structure and reduce the cost of capital.

The Trust has access to a number of capital sources, including: (i) cash on hand; (ii) internally generated cash flows; (iii) debt and other financing; (iv) the issuance of Trust Units to royalty sellers; and (v) future public equity issuances.

The Trust's primary ongoing source of liquidity is cash provided by operating activities. During the nine months ended September 30, 2025 the Trust generated \$64,601 (2024 – \$117,760) of cash provided by operating activities.

The Trust believes its existing capital resources and cash provided by operating activities will continue to allow the Trust to meet its operating and working capital requirements, and to meet externally imposed capital requirements and obligations, including the scheduled repayments of its credit facility for the foreseeable future.

As at September 30, 2025, the Trust was in compliance with all externally imposed capital requirements.

OFF-BALANCE SHEET OBLIGATIONS AND COMMITMENTS

On September 9, 2022, the Trust bought royalties on the sales of Zejula. In accordance with the terms of the royalty agreement, the Trust is committed to making a milestone payment of \$10,000 should Zejula be approved by the FDA for the treatment of endometrial cancer on or before December 31, 2025.

On November 25, 2022, the Trust bought royalties on the sales of Xenpozyme. In accordance with the terms of the royalty agreement, the royalty seller may be entitled to additional consideration of up to \$26,500 in the event that cumulative royalties received by the Trust on Xenpozyme sales exceed certain thresholds within a predefined period of time.

On April 3, 2023, the Trust bought an additional stream on Empaveli/Syfovre. In accordance with the terms of the royalty agreement, the royalty seller may be entitled to an additional payment of \$4,000 in the event that Empaveli/Syfovre sales exceed certain thresholds within a predefined period of time.

On August 16, 2023, the Trust entered into a pledge agreement with the Mayo Clinic. In accordance with the terms of the agreement, the Trust intends to contribute \$5,000 in total (\$1,000 annually, payable in quarterly installments) to the Mayo Clinic to directly support and further the Center for Regenerative Biotherapeutics. To date, the Trust has paid a total of \$2,250.

On February 1, 2024, the Trust amended the existing Omidria royalty agreement, as described on page 6 of this MD&A. In accordance with the terms of the amended royalty agreement, the royalty seller may be entitled to an additional payment of up to \$55,000 in potential sales-based milestone payments.

On June 28, 2024, the Trust bought an additional royalty stream on Xenpozyme, as described on page 7 of this MD&A. In accordance with the terms of the royalty agreement, the royalty seller may be entitled to additional consideration of up to \$32,500 in potential performance-based milestone payments.

On November 4, 2024, the Trust bought a royalty interest in Ekterly, as described on page 7 of this MD&A. In accordance with the terms of the royalty agreement, the royalty seller may be entitled to receive up to \$79,000, composed of up to \$57,000 in sales-based milestones and \$22,000 in a one-time optional payment. On July 7, 2025, after receiving FDA approval of Ekterly, the royalty seller elected to receive the one-time optional payment of \$22,000, increasing the royalty rate entitled by the Trust. After exercising the one-time optional payment, the royalty seller's potential one-time sales-based milestone payment increased to \$57,000 from \$50,000, contingent on annual worldwide net sales of Ekterly meeting or exceeding \$550,000 before January 1, 2031.

The Trust did not have any other off-balance sheet obligations, commitments or guarantees at September 30, 2025.

Subsequent to September 30, 2025, the Trust completed the veligrotug and VRDN-003 transaction as described on page 6 of this MD&A. In accordance with the terms of the royalty agreement, the royalty seller may be entitled to additional consideration of up to \$245,000 subject to the achieve of certain milestones, of which \$115,000 is related to near-term clinical and regulatory milestone payments.

RELATED-PARTY TRANSACTIONS

Persis Capital Inc. (formerly DRI Capital Inc.) served as the former external manager of the Trust until June 30, 2025. Management fees and performance fees were payable by the Trust pursuant to the management agreement prior to internalization. On July 1, 2025, the Trust completed the internalization transaction and termination of the management agreement, as described on page 5 of this MD&A, and as a result, management and performance fees are no longer payable by the Trust. The following related-party transactions occurred during the three and nine months ended September 30, 2025 and 2024.

Management fees

Prior to the termination of the management agreement, the Trust was required to pay quarterly management fees to the former external manager or its affiliates equal to 6.50% of total cash receipts for such quarter and 0.25% of the fair value of security investments and related derivative financial instruments as of the end of such quarter, as described in note 3(n) to the Trust's 2024 consolidated financial statements. During the three and nine months ended September 30, 2025, the Trust recorded management fees to the former external manager of nil and \$6,733, respectively (2024 – \$1,470 and \$8,459, respectively).

Performance fees

The former external manager was entitled to performance fees determined on a portfolio-by-portfolio basis pursuant to the terms of a management agreement, as described in note 3(o) to the Trust's 2024 consolidated financial statements.

The Trust recorded performance fees of nil and \$533 during the three and nine months ended September 30, 2025, respectively (2024 – nil and \$231, respectively), as the conditions for performance fees were met primarily due to the cash receipt of Casgevy in the first quarter of 2025.

During the fourth quarter of 2024, conditions for performance fee payments were met as a result of the additional revenue recognized for Orserdu, as described on page 4 of this MD&A, and performance fees of \$1,665 were recognized. During the nine months ended September 30, 2025, performance fees of \$2,198 were paid (2024 – \$6,149).

Other related party transactions

The Trust incurred other related party transactions with its former external manager during the three and nine months ended September 30, 2025 of \$252 (2024 – nil) and pertain primarily to transitional services provided by the former external manager for payroll and legal services that were in place prior to the internalization.

Key management compensation

During the three and nine months ended September 30, 2025 and 2024, the Trust issued compensation to members of the board of trustees of the Trust, as described on page 11 of this MD&A, and to certain officers of the Trust, as detailed below.

During the three and nine months ended September 30, 2025, the Trust recorded total cash compensation expense of \$962 and \$1,545, respectively (2024 – \$100 and \$100, respectively), related to compensation paid to certain officers of the Trust, including salaries, bonuses, and benefits. Included in cash compensation for the three and nine months ended September 30, 2025 is a one-time organizational restructuring cost of \$709 that is not expected to recur.

During the nine months ended September 30, 2025, the Trust granted 211,633 RUs to certain officers of the Trust, 99,254 of which vest equally on a quarterly basis beginning October 1, 2025 until July 1, 2026, 99,254 of which vest equally over three years on each anniversary date and 13,125 of which vest equally on April 1, 2026, April 1, 2027 and April 1, 2028.

During the nine months ended September 30, 2025, the Trust issued 23,338 Units on the settlement of vested RUs, net of withholding taxes, to certain officers of the Trust. To date, the Trust has issued a total of 74,789 Units on the settlement of vested RUs, of which 2,584 were issued in 2021, 3,376 were issued in 2022, 19,004 were issued in 2023, 26,487 were issued in 2024 and 23,338 were issued in 2025. During the three and nine months ended September 30, 2025, the Trust recorded unit-based compensation expense of \$914 and \$1,296, respectively (2024 – \$189 and \$806, respectively), related to the RU grants and the accretion of the related distribution equivalent Units.

Reimbursement

On July 9, 2024, based on the initial information at the start of the investigation into irregular expenses, the external manager reimbursed the Trust for \$5,501 (C\$7,500) which was recorded in other equity reserves on the date it was received. On August 6, 2024, the investigation was substantially completed and had identified \$6,510 in consulting and other expenses that had been incorrectly charged to the Trust as directed by the former Chief Executive Officer. On August 6, 2024, the Trust received an additional \$1,009 from the external manager related to the additional expenses identified from the investigation, \$696 of which was recorded in other equity reserves on the date received and \$314 of which reduced the related-party receivable from the external manager, as described on page 2 of this MD&A. Subsequent to August 6, 2024 the investigation concluded and no additional items were identified as requiring adjustment.

CHANGES IN ACCOUNTING POLICIES

The Trust's accounting policies are discussed in detail in note 3 to the Trust's 2024 consolidated financial statements. The following accounting policies have been modified or added in the current year, as described below.

Income taxes

The Trust is a mutual fund trust and a SIFT trust, as defined in the *Income Tax Act* (Canada). The Trust is not subject to income taxes provided that all of the Trust's taxable income is distributed to Unitholders each year in cash or by way of additional Units by the end of the fiscal year. Income distributed by the Trust is included in the tax returns of the Unitholders.

Certain entities, directly or indirectly owned by the Trust are subject to income taxes. The Trust accounts for income taxes in accordance with IAS 12, *Income Taxes*. Income tax expense for these subsidiaries reflect taxes payable on taxable income for the period, calculated based on the enacted or substantively enacted tax rates at the reporting date.

Leases

The Trust recognizes a right-of-use ("ROU") asset and a lease liability as at the lease commencement date in accordance with IFRS 16, *Leases*. The ROU asset is initially measured at cost which includes the initial lease liability, any lease payments made at or before the commencement date, and any direct costs incurred, and is subsequently depreciated on a straight-line basis over the lease term. The lease liability is initially measured at the present value of future lease payments over the anticipated lease term, discounted using the Trust's incremental borrowing rate. The ROU asset is presented in the other non-current assets line of the consolidated statements of financial position, and the short- and long-term portions of the lease liability are presented in the other current liabilities line and other non-current liabilities line, respectively, of the consolidated statements of financial position. Short-term leases under 12 months and leases of low-value assets are expensed as incurred.

Property, equipment and other intangible assets

Property, equipment and other intangible assets are recorded at cost. Finite-life assets are amortized on a straight-line basis over their expected useful life or in the case of leasehold improvements over the term of the lease. Subsequently, these assets are carried at cost less accumulated amortization and any accumulated impairment losses. Assets with indefinite useful lives are not amortized but are tested annually for impairment. The residual values, useful life and methods of amortization for property and equipment are reviewed at each reporting date and adjusted prospectively, if necessary. Any loss resulting from the impairment of property, equipment and other intangible assets is expensed in the period the impairment is identified.

CRITICAL ACCOUNTING ESTIMATES

In the preparation of this MD&A, the Trust has used consistent judgment and estimates as described in note 4 to the Trust's 2024 consolidated financial statements.

RISK FACTORS

Tariff risks

Our portfolio of royalty assets exposes us to potential risks associated with the imposition of tariffs on certain biotechnology and pharmaceutical products. The imposition of tariffs may result in additional gross-to-net deductions impacting top-line sales that the Trust earns royalties on, which would negatively impact our results of operations.

SUBSEQUENT EVENTS

Amendment to the amended credit agreement

On October 3, 2025, the Trust amended its amended credit agreement to, among other things, convert and merge the term credit facility into the acquisition credit facility. The total credit available under the acquisition credit facility increased by \$70,000 and the outstanding amount under the acquisition credit facility increased by an amount corresponding to the outstanding amount under the term credit facility as at October 3, 2025, which was \$63,250. This increased the total credit available under the acquisition credit facility to \$570,000. The Trust also extended the maturity date of the amended credit agreement by two years to October 3, 2029, which may be extended by one-year increments subject to lender approval. Certain other terms were also adjusted to provide the Trust with greater flexibility. All other material terms of the amended credit agreement remain unchanged.

Veligrotug and VRDN-003 transaction

On October 17, 2025, the Trust acquired a royalty interest in the U.S. net sales of veligrotug and VRDN-003 from Viridian Therapeutics, Inc. for an aggregate purchase price of up to \$300,000, including a \$55,000 upfront payment and up to \$115,000 in near-term clinical and regulatory milestone payments. The transaction entitles the Trust to 7.50% on annual U.S. net sales up to and including \$600,000, 0.80% on annual U.S. net sales above \$600,000 and up to and including \$900,000, and 0.25% on annual U.S. net sales above \$900,000 and up to and including \$2,000,000. Royalty receipts will be collected quarterly on a one-quarter lag, with the first royalty receipt being paid in the quarter immediately following the first commercial sale of veligrotug in the U.S.

The Trust drew \$50,000 from its acquisition credit facility to partially fund the Veligrotug and VRDN-003 transaction, with the remaining upfront payment being funded by internally generated cash.

NCIB repurchases

From the period of September 30, 2025 to November 5, 2025, the Trust acquired 53,076 Units under the May 2025 NCIB plan at an average price of \$10.28, totaling \$545 under the AUPP, as described on page 5 of this MD&A.

2025 fourth quarter distribution declared

On November 5, 2025, the board of trustees of the Trust declared a quarterly distribution of \$0.10 per Unit to Unitholders of record as at December 31, 2025 and payable on January 20, 2026.